

COMPLETE LIST OF PUBLICATIONS

(excluding abstract publications; *equal contribution)

ORIGINAL ARTICLES

2026

277. Bunse L, Lindner K, Wick A, Freitag A, Lanz LM, Edelmann D, Suwala A, Breckwoldt MO, Harting I, Sahm F, Schlenk RF, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Denk M, Walz J, Steinbach JP, von Deimling A, Schmitt M, Bunse T, Tabatabai G, Bendszus M, Poschke I, Wick W, Platten M. IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial. **Nat Cancer** 2026. Jul 1. doi: 10.1038/s43018-026-01199-y online ahead of print
276. Duerinck J, Van Den Bent M, Brandal P, Minniti G, Galldiks N, Franceschi E, Geurts M, Berghoff AS, Renovanz M, Brandsma D, Snijders TJ, Weller M, Short SC, Platten M, Le Rhun E, Preusser M, Schweizer L, Albert NL, Furtner J, Razis E. The European Association for Neuro-oncology (EANO) Consensus Statement on Radiation Necrosis. **Neuro Oncol** 2026. Jul 9: noag153. doi: 10.1093/neuonc/noag153 online ahead of print
275. Giordano FA, Laver JP, Turiello R, Friker LL, Mirallas O, Pregler BEF, Potthoff AL, Zeyen T, Weller J, Sperk E, Oster C, Kebir S, Hamsch P, Schäfer N, Kadzik S, Renovanz M, Pietsch T, Bisdas S, Sepúlveda-Sánchez JM, Gómez-Puerto D, Vieito M, Platten M, Gkika E, Grauer OM, Tabatabai G, Schneider M, Glas M, Seidel C, Herrlinger U, Hölzel M. L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial. **Nat Commun** 2026. 17(1):3405. doi: 10.1038/s41467-026-71362-7
274. Giorgetta S, Cortopassi F, Chanis T, Ni J, Correia MP, Sticht C, Ast V, Platten M, Cerwenka A, Stojanovic A. Functional segregation of HIF-1 α and AhR controls NK cell responsiveness under hypoxia. **iScience** 2026. 29(4):115492. doi: 10.1016/j.isci.2026
273. Grassl N, Suwala A, Kessler T, Bunse L, Mildenerberger I, Breckwoldt M, Ratliff M, Brehmer S, Herold-Mende C, Etminan N, Wick W, Sahm F, Platten M, Sahm K. Early distant progression in adult Histone-3 K27M-mutant diffuse midline gliomas. **J Neurooncol** 2026. 176(2):166. doi: 10.1007/s11060-025-05238-z
272. Kaulen LD, Nayak L, Karschnia P, Kraai I, Galluzzo DR, de Groot FA, Witterholt M, Donovan L, Bhella S, Kuschel LP, Fox CP, Seidel S, Paterson J, Richter B, Dixit KS, Zeyen T, Alderuccio JP, Montoto S, Kuittinen O, Traub BL, Doubrovinskaia S, Rohdjes H, Mueller K, Enting R, de Bresser J, Kuitunen H, Iwamoto FM, Alencar AJ, Herrlinger U, Platten M, Cwynarski K, Mendez JS, Roth P, von Baumgarten L, Prica A, Bhagat G, Lurain K, Schiff D, Vermaat JS, Baehring J, Nijland M, Dietrich J, Batchelor TT, Wick W. Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study. **Blood** 2026. 148(1):58-70. doi: 10.1182/blood.2025031869
271. Kourtesakis A, Chow HNH, Bailey E, Horschitz S, Jabali A, Will R, Schifflers C, Suwala A, Rohdjes H, Hahn M, Chih YC, Hai L, Reibold D, Pusch S, Agardy DA, Hoffmann D, Wagener R, Kaulen L, Bunse L, Platten M, Sahm F, Müller-Tidow C, Schmitt M, Wick W, Sauer T, Kessler T. A comparative analysis of CD70-directed CAR-T cells for glioblastoma treatment demonstrates a superior efficacy of the ligand-based construct. **Mol Ther Oncol** 2026. 34(1):201134. doi: 10.1016/j.omton.2026.201134
270. Lazaridis L, Pepper NB, Klein P, Oster C, Agkatsev S, Mildenerberger I, Berg R, Seidel S, Sharma S, Bodensohn R, Hau P, Tabatabai G, Roser P, Mallmann B, Kleinschnitz C, Sure U, Seliger C, Glas M, Platten M, Combs S, Muther M, Kebir S. End-of-life challenges in neuro-oncological patient care: A survey from the Junge Neuroonkologische Arbeitsgemeinschaft. **Neurooncol Pract** 2026. 13(3):528-536. doi: 10.1093/nop/npaf123

269. Maas SLN, Tang Y, Stutheit-Zhao E, Rahmanzade R, Blume C, Hielscher T, Zettl F, Benfatto S, Calafato D, Sill M, Benotmane JK, Yabo YA, Behling F, Suwala A, Kardo H, Ritter M, Peyre M, Sankowski R, Okonechnikov K, Sievers P, Patel A, Reuss D, Friedrich MJ, Stichel D, Schrimpf D, Van den Bosch TPP, Beck K, Wirsching HG, Jungwirth G, Hanemann CO, Lamszus K, Etminan N, Unterberg A, Mawrin C, Remke M, Ayrault O, Lichter P, Reifenberger G, Platten M, Kacprowski T, List M, Pauling JK, Baumbach J, Milde T, Grossmann R, Ram Z, Ratliff M, Mallm JP, Neidert MC, Bos EM, Prinz M, Weller M, Acker T, Hartmann FJ, Preusser M, Tabatabai G, Herold-Mende C, Krieg SM, Jones DTW, Pfister SM, Wick W, Kalamarides M, von Deimling A, Heiland DH, Hovestadt V, Gerstung M, Schlesner M; German "Aggressive Meningiomas" Consortium (KAM); Sahm F. A microenvironment-determined risk continuum refines subtyping in meningioma and reveals determinants of machine learning-based tumor classification. **Nat Genet** 2026. 58(2):341-354. doi: 10.1038/s41588-025-02475-w
268. Michel JJ, Sanghvi K, Rosenbauer J, Humbs L, Dierssen CT, Grudzenski-Theis S, Sachs V, Jähne K, Degenhardt K, Frölich L, Herms J, Fatar M, Platten M, Bunse L. Type I interferon drives T cell responses to amyloid beta in the central nervous system. **Nat Commun** 2026. 17(1):3737. doi: 10.1038/s41467-026-72262-6
267. Scheck JG, Boztepe B, Kernbach JM, Karimian-Jazi K, Heinz L, Schregel K, Sturm V, Schell M, Bojcevski J, Fischer M, Eurich R, Poschke I, Schwarz J, Agardy DA, Jünger S, Schulz C, Althammer F, Osidach AR, Abdollahi A, Bunse L, Venkataramani V, Pfister SM, Winkler F, Kessler T, Wick W, Heiland S, Platten M, Rodell C, Bendszus M, Weidenfeld I, Breckwoldt MO. Multimodality mapping of immunotherapy distribution as a predictive marker in glioma. **Neuro Oncol** 2026. 28(4):1038-1052. doi: 10.1093/neuonc/noaf295
266. Seferbekova Z, Ritter M, Ruckhovich G, Schinkewitsch S, Köberer N, Grassl N, Deng MY, Ruder AM, König L, Debus J, Hanning U, Giordano FA, Kessler T, Goidts V, Ratliff M, Herold-Mende C, Krieg SM, Etminan N, Platten M, Wick W, Reuss D, Von Deimling A, Sahm F, Gerstung M, Suwala AK. Spatial Transcriptomics Characterisation of Radionecrotic Changes in Glioblastoma Patients. **Neuro Oncol** 2026. 28(5):1150-1162. doi: 10.1093/neuonc/noag026
265. Sester LS, Galeeva I, de Castilhos J, Borisov V, Gambihler A, Kilian M, Vonhören D, Friedrich MJ, Poschet G, Steiger S, Chechenina A, Lettau K, Kohlberger CP, Prokoph N, Frenking JH, John L, Huhn S, Reichert P, Mai EK, Rippe K, Sauer S, Müller-Tidow C, Weinhold N, Platten M, Goldschmidt H, Raab MS, Stein-Thoeringer CK. Fiber intake associates with increased treatment response in multiple myeloma patients along changes in gut microbiome. **Blood Adv** 2026. 10(9):3088-3093. doi: 10.1182/bloodadvances.2025018598
264. Sill M, Schrimpf D, Patel A, [...], Platten M, [...], Sahm, F. Advancing CNS tumor diagnostics with expanded DNA methylation-based classification. **Cancer Cell** 2026. 44(2):340-354.e2. doi: 10.1016/j.ccell.2025.11.002
263. Silva-Bermudez LS, Streuer A, Christodoulou F, Eisele P, Steiner L, Metzgeroth G, Platten M, Hofmann WK, Abba ML. Gilteritinib in an Isolated CNS Recurrence of FLT3-ITD Positive AML. **Clin Case Rep** 2026. 14(1):e71541. doi: 10.1002/ccr3.71541
262. Suwala AK, Friedel D, Hinz FE, Mahlknecht PD, Schinkewitsch S, Rieder M, Fernandez NR, Stengs L, Chang Y, Ringel A, Haag D, Pusch S, Stichel D, Schrimpf D, Kramm CM, Wesseling P, Schweizer L, Harter P, Hartmann C, Capper D, Snuderl M, Boldt H, Brandner S, Dohmen H, Acker T, Schittenhelm J, Hasselblatt M, Agardy D, Bunse T, Bunse L, Korshunov A, Herold-Mende C, Etminan N, Wick W, Platten M, Das A, Tabori U, Blattner-Johnson M, Sill M, Sturm D, Pfister SM, Jones DT, Sahm F, von Deimling A, Reuss DE. Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all Ages. **Neuro Oncol** 2026. Jun 3: noag132. doi: 10.1093/neuonc/noag132 online ahead of print
261. Tabatabai G, Ramirez I, Welte B, Bombach P, Becker H, Bernhardt D, Mayer-Steinacker R, Meier F, Neidert N, Roelz R, Mildenerberger I, Bunse L, Platten M, Herrlinger U, Martens UM, Ernemann U, Neumann M, Tatagiba M, Serna-Higueta LM, Martus P, Renovanz M. Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial. **Nat Cancer** 2026. 7(7):1094-1103. doi: 10.1038/s43018-026-01185-4
260. Zhang X, Kamiyama M, Tulessin M, Rinck L, Mallm JP, Kilian M, Agardy DA, Heikenwälder M, Platten M, Mogler C, Singhal M, Augustin HG. LPL-Positive Endothelial Cells Control T-cell Homing in Liver Metastasis. **Cancer Discov** 2026. Jul 20:OF1-OF21. doi: 10.1158/2159-8290.CD-25-1411 online ahead of print

2025

259. Hinz FE, Friedel D, Ippen FM, Sill M, Korshunov A, Schweizer L, Schrimpf D, Göbel K, Friedrich LS, Aras FK, Bogumil H, Banan R, Dohmen H, Acker T, Brandner S, Schmid S, Capper D, Grassl N, Boldt HB, Wesseling P, Maas SLN, Martinez JPG, Stadelmann C, Reifenberger G, Stehle T, Barrantes-Freer A, Juratli TA, Pusch S, Haag D, Reuss DE, Herold-Mende C, Krieg S, Wick W, Etminan N, Platten M, Pfister SM, Jones DTW, Sahm F, von Deimling A, Suwala AK. Loss of global DNA hypermethylation is prognostic in IDH-mutant and 1p/19q-codeleted oligodendrogliomas. **Acta Neuropathol** 2025. 150:56. doi: 10.1007/s00401-025-02963-7
258. Lindner K, Stange SR, Hlawatsch J, Hamberger M, Boschert T, Tan CL, Hülsmeier I, Sachse SM, Jünger S, Ernst A, Glatki O, Vinogradova S, Fleischhacker L, Eichmüller SB, Fröhling S, Hassel J, Zörnig I, Lyu Y, Huang Z, Jäger D, Momburg F, Meyer M, Bunse L, Green EW, Platten M, Poschke I. ESPEC-SUIT A versatile and robust platform to identify and track antigen-specific T cell receptors in cancer patients. **J Immunother Cancer** 2025. 13:e012216. doi: 10.1136/jitc-2025-012216
257. Wohlfeil SA, Weller C, Dietsch B, Agardy DA, Boschert T, Häfele V, Platten M, Goerdts S, Géraud C. Neoadjuvant immune checkpoint inhibition protects against hepatic melanoma metastasis with an anti-tumor Th1 immune response. **Cancer Lett** 2025. 632:217950. doi: 10.1016/j.canlet.2025.217950
256. Kourtesakis A, Bailey E, Chow HNH, Rohdjes H, Mussnig N, Agardy D, Hoffmann D, Chih YC, Will R, Kaulen L, Hahn M, Wagener R, Reibold D, Pusch S, Sahm F, Sauer T, Schmitt M, Bunse L, Platten M, Wick W, Kessler T. Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma. **Oncoimmunol** 2025. 14:2518631. doi: 10.1080/2162402X.2025.2518631
255. Wick W, Lanz LM, Wick A, Harting I, Dettmer S, Suwala AK, Ketter R, Tabatabai G, Seliger-Behme C, Glas M, Burger MC, Timmer M, Ringel FA, Mildnerberger I, Schulz-Schaeffer WJ, Winkler F, König L, Herold-Mende C, Eisenmenger A, Pfister SM, Renovan M, Bendszus M, Sahm F, Platten M, Kessler T. Molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (N2M2/NOA-20 phase I/IIa umbrella trial). **Nat Med** 2025. 31:3534-3541. doi: 10.1038/s41591-025-03928-9
254. Szabo K, Obertacke U, Sandikci V, Ghanayem S, Alonso A, Rink JS, Marzina A, Platten M, Hoyer C. Mind the guideline gap: emergent CT in patients with epilepsy for trauma rule-out-A retrospective cohort study. **Neurol Res Pract** 2025. 7:10. doi: 10.1186/s42466-025-00370-7
253. Santhanam N, Kim HE, Rügamer D, Bender A, Muthers S, Cho CG, Alonso A, Szabo K, Centner FS, Wenz H, Ganslandt T, Platten M, Groden C, Neumaier M, Siegel F, Maros ME. Machine learning-based forecasting of daily acute ischemic stroke admissions using weather data. **NPJ Digit Med** 2025. 8:225. doi: 10.1038/s41746-025-01619-w
252. Sandikci V, Ebert A, Marzina A, Platten M, Szabo K, Hoyer C. Hippocampal contributions to semantic memory retrieval: strategy-specific impairments in transient global amnesia. **J Neuropsychol** 2025. 9:591-602. doi: 10.1111/jnp.12430
251. Peng T, Ma X, Hua W, Wang C, Chu Y, Sun M, Fermi V, Hamelmann S, Lindner K, Shao C, Zaman J, Tian W, Zhuo Y, Harim Y, Stöffler N, Hamann L, Xiao Q, Jin X, Warta R, Lotsch C, Zhuang X, Feng Y, Fu M, Zhang X, Zhang J, Xu H, Qiu F, Xie L, Zhang Y, Zhu W, Du Z, Salgueiro L, Schneider M, Eichhorn F, Lefevre A, Pusch S, Grinevich V, Ratliff M, Loges S, Bunse L, Sahm F, Xiang Y, Unterberg A, von Deimling A, Platten M, Herold-Mende C, Wu Y, Liu HK, Mao Y. Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy. **Cell Stem Cell** 2025. 32:652-669.e11. doi: 10.1016/j.stem.2025.01.002
250. Chih YC, Dietsch AC, Koopmann P, Ma X, Agardy DA, Zhao B, De Roia A, Kourtesakis A, Kilian M, Krämer C, Suwala AK, Stenzinger M, Boenig H, Blum A, Pienkowski VM, Aman K, Becker JP, Feldmann H, Bunse T, Harbottle RP, Riemer AB, Liu HK, Etminan N, Sahm F, Ratliff M, Wick W, Platten M, Green EW, Bunse L. Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen. **Nat Commun** 2025. 16:1262. doi: 10.1038/s41467-025-56547-w
249. Raghavan R, Friedrich MJ, King I, Chau-Duy-Tam Vo S, Strebing D, Lash B, Kilian M, Platten M, Macrae RK, Song Y, Nivon L, Zhang F. Rational engineering of minimally immunogenic nucleases for gene therapy. **Nat Commun** 2025. 16:105. doi: 10.1038/s41467-024-55522-1

248. Karimian-Jazi K, Enbergs N, Golubtsov E, Schregel K, Ungermann J, Fels-Palesandro H, Schwarz D, Sturm V, Kernbach J, Batra D, Ippen F, Pflüger I, von Knebel Doeberitz N, Heiland S, Platten M, Winkler F, Wick W, Paech D, Bendszus M, Breckwoldt MO. Assessing metabolic heterogeneity and invasion patterns in glioma recurrence by APTw CEST MRI. **Invest Radiol** 2025. 60:414-422. doi: 10.1097/RLI.0000000000001145
247. Tan C, Lindner K, Boschert T, Meng Z, Rodriguez Ehrenfried A, De Roia A, Haltenhof G, Faenza A, Imperatore F, Bunse L, Lindner JM, Harbottle RP, Ratliff M, Offringa R, Poschke I, Platten M*, Green EW*. Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalised T cell therapy. **Nat Biotechnol** 2025. 43:134-142. doi: 10.1038/s41587-024-02161-y

2024

246. Dirven L, Machingura A, van den Bent MJ, Coens C, Bottomley A, Brandes AA, Domont J, Idbaih A, Koekkoek JAF, Reijneveld JC, Platten M, Wick W, Taphoorn MJB. Health-related quality of life in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only: Secondary outcome of the randomized phase III EORTC 26101 study. **Neuro-Oncol Pract** 2024. 12:209-218. doi: 10.1093/nop/npae091
245. Malmström A, Oppong FB, O'Callaghan CJ, Wick W, Laperriere N, Gorlia T, Weller M, Henriksson R, Mason W, Platten M, Cantagallo E, Grønberg BH, Reifenberger G, Marosi C*, Perry JR* for the NCBTSG, NOA, CCTG and EORTC Brain Tumor Group. Prognostic factors for overall survival in elderly patients with glioblastoma: Analysis of the pooled NOA-08 and Nordic trials with the CCTG-EORTC (CE.6) trial. **Neuro-Oncol Adv** 2024. 6:vdae211. doi: 10.1093/oaajnl/vdae211
244. Salek M*, Förster JD*, Becker JP*, Meyer M, Charoentong P, Lyu Y, Lindner K, Lotsch C, Volkmar M, Momburg F, Poschke I, Fröhling S, Schmitz M, Offringa R, Platten M, Jäger D, Zörnig I, Riemer AB. optIPRM: A targeted immunopeptidomics LC-MS workflow with ultra-high sensitivity for the detection of mutation-derived tumor neoepitopes from limited input material. **Mol Cell Proteomics** 2024. 23:100825. doi: 10.1016/j.mcpro.2024.100825
243. Streibel Y, Breckwoldt MO, Hunger J, Pan C, Fischer M, Turco V, Boztepe B, Fels-Palesandro H, Scheck JG, Sturm V, Karimian-Jazi K, Agardy DA, Annio G, Mustapha R, Weidenfeld I, Soni SS, Alasa A, Rodell CB, Wick W, Heiland S, Winkler F, Platten M, Bendszus M, Sinkus R, Schregel K. Tumor biomechanics as a novel imaging biomarker to assess response to immunotherapy in a murine glioma model. **Sci Rep** 2024. 14:15613. doi: 10.1038/s41598-024-66519-7
242. Gellert J, Agardy D, Kumar S, Kourtesakis A, Boschert T, Jaehne K, Breckwoldt M, Bunse L, Wick W, Davies M, Platten M, Bunse T. Tumoral Interferon Beta Induces an Immune-Stimulatory Phenotype in Tumor-Associated Macrophages in Melanoma Brain Metastases. **Cancer Res Commun** 2024. 4:2189-2202. doi: 10.1158/2767-9764.CRC-24-0024
241. Dobersalske C, Rauschenbach L, Hua Y, Berliner C, Steinbach A, Grüneboom A, Kokkaliaris K, Heiland DH, Berger P, Langer S, Tan CL, Stenzel M, Landolsi S, Weber F, Oppong MD, Werner RA, Gull H, Schröder T, Linsenmann T, Buck A, Gunzer M, Stuschke M, Keyvani K, Forsting M, Glas M, Kipnis J, Steindler DA, Reinhardt C, Green EW, Platten M, Tasdogan A, Herrmann K, Rambow F*, Cima I*, Sure U*, Scheffler B*. Cranioencephalic functional lymphoid units in glioblastoma. **Nat Med** 2024. 30:2947-2956. doi: 10.1038/s41591-024-03152-x
240. Wischniewski S*, Thäwel T*, Ikenaga C*, Kocharyan A*, Lerma-Martin C, Zulji A, Rausch HW, Brenner D, Thomas L, Kutza M, Wick B, Trobisch T, Preusse C, Haeussler M, Leipe J, Ludolph A, Rosenbohm A, Hoke A, Platten M, Weishaupt JH, Sommer CJ, Stenzel W, Lloyd TE, Schirmer L. Cell type mapping of inflammatory muscle diseases highlights selective myofiber vulnerability in inclusion body myositis. **Nat Aging** 2024. 4:969-983. doi: 10.1038/s43587-024-00645-9
239. Becker L, Alonso A, Kruska M, Baumann S, Grassl N, Lesch H, Eisele P, Sieburg T, Behnes M, Schupp T, Kayed H, Platten M, Duerschmied D, Szabo K, Akin I, Fastner C. [Acute ischemic stroke and troponin elevation: update of the Mannheim clinical algorithm]. **Innere Med (Heidelb)** 2024. 65:830-839. doi: 10.1007/s00108-024-01719-x
238. Giordano FA, Layer JP, Leonardelli S, Friker LL, Turiello R, Corvino D, Zeyen T, Schaub C, Müller W, Sperk E, Schmeel LC, Sahm K, Oster C, Kebir S, Hamsch P, Pietsch T, Bisdas S, Platten M, Glas M, Seidel C, Herrlinger U, Hölzel M. L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial. **Nat Commun** 2024. 15:4210. doi: 10.1038/s41467-024-48416-9

237. Kilian M*, Friedrich MJ*, Lu KH*, Vonhören D, Jansky S, Michel J, Keib A, Stange S, Hackert N, Kehl N, Hahn M, Habel, Jung S, Jähne K, Sahm F, Betge J, Cerwenka A, Westermann F, Dreger P, Raab MS, Meindl-Beinker NM, Ebert MP, Bunse L, Müller-Tidow C, Schmitt M, Platten M. The Ig superfamily ligand B7H6 subjects T cell responses to NK cell surveillance. **Sci Immunol** 2024. 9:eadj7970. doi: 10.1126/sciimmunol.adj7970
 236. Rastogi A, Brugnara G, Foltyn-Dumitru M, Mahmutoglu MA, Preetha CJ, Pflüger I, Schell M, Kobler E, Deike-Hofmann K, Kessler T, van den Bent MJ, Idhah A, Platten M, Brandes AA, Nabors B, Stupp R, Bernhardt D, Debus J, Abdollahi A, Gorlia T, Prof. Tonn JC, Weller M, Maier-Hein KH, Radbruch A, Wick W, Prof. Bendszus M, Kurz F, Meredig H, Vollmuth P. Deep-learning-based reconstruction of undersampled MRI for multi-fold reduction of scan time: a multicenter retrospective cohort study in neuro-oncology. **Lancet Oncol** 2024. 25:400-10. doi: 10.1016/S1470-2045(23)00641-1
 235. Cetin M*, Pinamonti V*, Schmid T*, Boschert T, Mellado Fuentes A, Kromer K, Lerner T, Zhang J, Herzig Y, Ehlert C, Hernandez-Hernandez M, Samaras G, Torres CM, Fisch L, Dragan V, Kouwenhoven A, Van Schoubroeck B, Wils H, Van Hove C, Platten M, Green E, Stevenaert F, Felix NJ, Lindner JM. T-FINDER: A highly sensitive, pan-HLA platform for functional T cell receptor and ligand discovery. **Sci Adv** 2024. 10:eadk3060. doi: 10.1126/sciadv.adk3060
 234. Boschert T*, Kromer K*, Lerner T*, Lindner K, Haltenhof G, Tan CL, Jähne K, Poschke I, Bunse L, Grassl N, Mildenerberger I, Sahm K, Platten M, Lindner JM*, Green EW*. H3K27M neopeptide vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient. **Sci Adv** 2024. 10:eadi9091. doi: 10.1126/sciadv.adi9091
 233. Iser F, Hinz F, Hoffmann D, Graßl N, Güngör C, Meyer J, Dörner L, Hofmann L, Kelbch V, Göbel K, Mahmutoglu M, Vollmuth P, Patel A, Nguyen D, Maaß K, Pajtlér KW, Schankar G, Weiler M, Wildemann B, Platten M, Wick W, Sahm F*, Kessler T*. Cerebrospinal fluid cfDNA sequencing for classification of central nervous system glioma. **Clin Cancer Res** 2024. 30:2974-2985. doi: 10.1158/1078-0432.CCR-23-2907
 232. Meyer M, Parpoulas C, Barthélémy T, Becker JP, Charoentong P, Lyu Y, Börsig S, Bulbuc N, Tessmer C, Weinacht L, Ibberson D, Schmidt P, Pipkorn R, Eichmüller SB, Steinberger P, Lindner K, Poschke I, Platten M, Fröhling S, Riemer AB, Hassel JC, Roberti MP, Jäger D, Zörnig I, Momburg F. MediMer: A versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection. **Front Immunol** 2024. 14:1294565. doi: 10.3389/fimmu.2023.1294565
- 2023**
231. Sahm K, Kessler T, Eisele P, Ratliff M, Sperk E, König L, Breckwoldt MO, Seliger C, Mildenerberger I, Schrimpf D, Herold-Mende C, Zeiner PS, Tabatabai G, Meuth SG, Capper D, Bendszus M, von Deimling A, Wick W, Sahm F, Platten M. Concurrent gliomas in patients with multiple sclerosis. **Commun Med** 2023. 3:186. doi: 10.1038/s43856-023-00381-y
 230. Van NT, Zhang K, Wigmore RM, Kennedy AI, DaSilva CR, Huang J, Ambelil M, Villagomez JH, O'Connor GJ, Longman RS, Cao M, Snook AE, Platten M, Kasenty G, Sigal LJ, Prendergast GC, Kim SV. Dietary L-Tryptophan consumption determines the number of colonic regulatory T cells and susceptibility to colitis via GPR15. **Nat Commun** 2023. 14:7363. doi: 10.1038/s41467-023-43211-4
 229. Kober C, Roewe J*, Schmees N, Roese L, Roehn U, Bader B, Stoeckigt D, Prinz F, Gorjánác M, Roeder HG, Olesch C, Leder G, Irlbacher H, Lesche R, Lefranc J, Oezcan-Wahlbrink M, Sati Batra A, Elmadany N, Carretero R, Sahm K, Oezen I, Cichon F, Baumann D, Sadik A, Opitz C, Weinmann H, Hartung IV, Kreft B, Offringa R, Platten M*, Gutcher I*. Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964, a selective small molecule inhibitor for cancer immunotherapy. **J Immunother Cancer** 2023. 11:e007495. doi: 10.1136/jitc-2023-007495
 228. Hunger J, Schregel K, Boztepe B, Agardy DA, Turco V, Karimian-Jazi K, Weidenfeld I, Streibel Y, Fischer M, Sturm V, Kourtesakis A, Santarella-Mellwig R, Kilian M, Jähne K, Sahm K, Wick W, Bunse L, Heiland S, Bunse T, Bendszus M, Platten M, Breckwoldt MO. In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma. **Theranostics** 2023. 13:5170-5182. doi: 10.7150/thno.87248
 227. Alonso A, Kraus J, Ebert A, Nikolayenko V, Kruska M, Sandikci V, Lesch H, Duerschmied D, Platten M, Baumann S, Szabo K, Akin I, Fastner C. Left atrial area index provides the best prediction of atrial fibrillation in ischemic stroke patients: results from the LAETITIA observational study. **Front Neurol** 2023. 14:1237550. doi: 10.3389/fneur.2023.1237550

226. Grassl N*, Sahm K*, Süße H, Poschke I, Bunse L, Bunse T, Boschert T, Mildenerger I, Rupp AK, Ewinger MP, Lanz LM, Denk M, Tabatabai G, Ronellenfisch MW, Herrlinger U, Glas M, Krex D, Vajkoczy P, Wick A, Harting I, Sahm F, von Deimling A, Bendszus M, Wick W, Platten M. INTERCEPT H3: A multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas. **Neurol Res Pract** 2023. 5:55. doi: 10.1186/s42466-023-00282-4
225. Hofmann A, Krajnc N, Dal-Bianco A, Riedl CJ, Zrzavy T, Lerma-Martin C, Kasprian G, Weber CE, Pezzini F, Leutmezer F, Rommer P, Bsteh G, Platten M, Gass A, Berger T, Eisele P, Magliozzi R, Schirmer L, Hametner S. Myeloid cell iron uptake pathways and paramagnetic rim formation in multiple sclerosis. **Acta Neuropathol** 2023. 146:707-724. doi: 10.1007/s00401-023-02627-4
224. Grassl N, Poschke I, Lindner K, Bunse L, Mildenerger I, Boschert T, Jähne K, Green EW, Hülsmeier I, Jünger S, Kessler T, Suwala A, Sahm F, Eisele P, Breckwoldt MO, Vajkoczy P, Grauer OM, Herrlinger U, Tonn JC, Denk M, Bendszus M, von Deimling A, Winkler F, Wick W, Platten M*, Sahm K*. A H3K27M-targeted vaccine in adults with diffuse midline glioma. **Nat Med** 2023. 29:2586-2592. doi: 10.1038/s41591-023-02555-6
223. Krämer C, Kilian M, Chih YC, Kourtesakis A, Hoffmann D, Boschert T, Koopmann P, Sanghvi K, De Roia A, Jung S, Jähne K, L. Shultz D, Harbottle R, Green EW, Will R, Wick W, Platten M, Bunse L. NLGN4X TCR transgenic T cells to treat gliomas. **Neuro-Oncol** 2023. 26(2):266-27. doi: 10.1093/neuonc/noad172
222. Nold AK, Wittayer M, Weber CE, Platten M, Gass A, Eisele P. Short-term dynamics of brain atrophy development after initiation of immunomodulatory treatment in a real world multiple sclerosis cohort. **J Neuroimag** 2023. 33:904-908. doi: 10.1111/jon.13146
221. Kessler T, Schrimpf D, Doerner L, Hai L, Kaulen L, Ito J, van den Bent M, Taphoorn MJB, Brandes AA, Idbaih A, Dörmont J, Clement PMJ, Campone M, Bendszus M, von Deimling A, Sahm F, Platten M, Wick W, Wick A. Prognostic markers of DNA methylation and NGS 1 sequencing in progressive glioblastoma from the 2 EORTC-26101 trial. **Clin Cancer Res** 2023. 29:3892-3900. doi: 10.1158/1078-0432.CCR-23-0926
220. Papaioannou S*, See JX*, Jeong M, De La Torre C, Reiners-Koch P, Sati A, Mogler C, Platten M, Cerwenka A*, Stojanovic A*. Liver sinusoidal endothelial cells orchestrate NK cell recruitment and activation in acute inflammatory liver injury. **Cell Rep** 2023. 42:112836. doi: 10.1016/j.celrep.2023.112836
219. Schregel K, Heinz L, Hunger J, Pan C, Bode J, Fischer M, Sturm Venkataramani V, Karimian-Jazi K, Agardy D, Streibel Y, Zerelles R, Wick W, Heiland S, Bunse T, Tews B, Platten M, Winkler F, Bendszus M, Breckwoldt M. A cellular ground truth to develop MRI signatures in glioma models by correlative light sheet microscopy and atlas-based co-registration. **J Neurosci** 2023. 43:5574-5587. doi: 10.1523/JNEUROSCI.1470-22.2023
218. Friedrich MJ*, Neri P*, Kehl N, Michel J, Steiger S, Kilian M, Leblay N, Maity R, Sankowski R, Lee H, Barakat E, Ahn S, Weinhold N, Rippe K, Bunse L, Platten M, Müller-Tidow C, Goldschmidt H, Raab MS*, Bahlis NJ*. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. **Cancer Cell** 2023. 41:1-15. doi: 10.1016/j.ccell.2023.02.008
217. Sammour DA, Cairns JL, Boskamp T, Marsching C, Kessler T, Guevara CR, Panitz V, Sadik A, Cordes J, Schmidt S, Mohammed SA, Rittel MF, Friedrich M, Platten M, Wolf I, von Deimling A, Opitz CA, Wick W, Hopf C. Spatial Probabilistic Mapping of Metabolite Ensembles in Mass Spectrometry Imaging. **Nat Commun** 2023. 14:1823. doi: 10.1038/s41467-023-37394-z
216. Kapell H, Fazio L, Dyckow J, Schwarz S, Cruz-Herranz A, Campos J, Mayer C, D'Este E, Möbius W, Cordano C, Pröbstel AK, Gharagozloo M, Zulji A, Naik VN, Delank A, Cerina M, Müntefering T, Lerma-Martin C, Sonner JK, Sin JH, Disse P, Rychlik N, Sabeur K, Chavali M, Srivastava R, Heidenreich M, Fitzgerald KC, Seeböhm G, Stadelmann C, Hemmer B, Platten M, Jentsch TJ, Engelhardt M, Budde T, Nave KA, Calabresi PA, Friese MA, Green AJ, Acuna C, Rowitch DH, Meuth SG, Schirmer L. Neuron-oligodendrocyte potassium shuttling at nodes of Ranvier as a neuroprotective target during inflammatory demyelination. **J Clin Invest** 2023. 133:e164223. doi: 10.1172/JCI164223
215. Turco V, Pfeleiderer K, Hunger J, Horvat NK, Karimian-Jazi K, Schregel K, Fischer M, Brugnara G, Jähne K, Sturm V, Streibel Y, Nguyen D, Altamura S, Agardy DA, Soni SS, Alsasa A, Bunse T, Schlesner M, Muckenthaler MU, Weissleder R, Wick W, Heiland S, Vollmuth P, Bendszus M, Rodell CB, Breckwoldt MO*, Platten M*. T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles. **Nat Commun** 2023. 14:771. doi: 10.1038/s41467-023-36321-6
214. Wittayer M, Weber CE, Kittel M, Platten M, Schirmer L, Tumani H, Gass A, Eisele P. Cerebrospinal fluid-related tissue damage in multiple sclerosis patients with iron rim lesions. **Mult Scler** 2023. 29:549-558. doi: 10.1177/13524585231155639

213. Abu Hejleh AP, Huck K, Jähne K, Tan CL, Lanz TV, Epping L, Sonner JK, Meuth SG, Henneberg A, Opitz CA, Herold-Mende C, Sahm F, Platten M, Sahm K. Endothelial indoleamine-2,3-dioxygenase-1 is not critically involved in regulating antitumor immunity in the central nervous system. **Int J Tryptophan Res** 2023. 16:11786469231153111. doi: 10.1177/11786469231153111
212. Wenzel N, Wittayer M, Weber CE, Platten M, Gass A, Eisele P. Multiple sclerosis iron rim lesions are linked to impaired cervical spinal cord integrity using the T1/T2-weighted ratio. **J Neuroimaging** 2023. 33:240-246. doi: 10.1111/jon.13076
211. Le Rhun E, Oppong FB, van den Bent M, Wick W, Brandes AA, Taphoorn MJ, Platten M, Idbaih A, Clement PM, Preusser M, Golfopoulos V, Gorlia T, Weller M. Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101. **Eur J Cancer** 2023. 178:13-22. doi: 10.1016/j.ejca.2022.10.006
210. Kilian M*, Sheinin R*, Tan CL, Krämer C, Friedrich M, Kaminitz A, Sanghvi K, Lindner K, Chih YC, Cichon F, Richter B, Jung S, Jähne K, Ratliff M, Prins R, Etminan N, von Deimling A, Wick W, Madi A*, Bunse L*, Platten M*. MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. **Cancer Cell** 2023. 41:1-17. doi: 10.1016/j.ccell.2022.12.007
209. Wittayer M, Weber CE, Krämer J, Platten M, Schirmer L, Gass A, Eisele P. Exploring (peri-) lesional and structural connectivity tissue damage through T1/T2-weighted ratio in iron rim multiple sclerosis lesions. **Magn Reson Imag** 2023. 95:12-18. doi: 10.1016/j.mri.2022.10.009
208. Friedrich M, Hahn M, Michel J, Sankowski R, Kilian M, Kehl N, Günter M, Bunse T, Pusch S, von Deimling A, Wick W, Autenrieth SE, Prinz M, Platten M, Bunse L. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma. **Neuro-Oncol** 2023. 25(2):263-276. doi: 10.1093/neuonc/noac138

2022

207. Manta CP*, Leibing T*, Friedrich M, Nolte H, Adrian M, Schledzewski K, Krzietzko J, Kirkamm C, Xi Y, Stojanovic A, Tonack S, De la Torre C, Hammad S, Offermanns S, Krüger M, Cerwenka A, Platten M, Goerdts S*, Géraud C*. Targeting of scavenger receptors Stabilin-1 and Stabilin-2 ameliorates atherosclerosis by a plasma proteome switch mediating monocyte/macrophage suppression. **Circulation** 2022. 146:1783-1799. doi: 10.1161/CIRCULATIONAHA.121.058615
206. Kehl N, Kilian M, Michel J, Wagner TR, Uhrig S, Brobeil A, Sester LS, Blobner S, Steiger S, Hundemer M, Weinhold N, Rippe K, Fröhling S, Eichmüller S, Bunse L, Müller-Tidow C, Goldschmidt H, Platten M, Raab MS, Friedrich M. IgE Type Multiple Myeloma Exhibiting Hypermutated Phenotype and Tumor Reactive T Cells. **J Immunother Cancer** 2022. 10:e005815. doi: 10.1136/jitc-2022-005815
205. Lu K, Michel J, Kilian M, Aslan K, Qi H, Kehl N, Jung S, Sanghvi K, Lindner K, Zhang XW, Green EW, Poschke I, Ratliff M, Bunse T, Sahm F, von Deimling A, Wick W, Platten M, Bunse L. T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells. **Neuro-Oncol Adv** 2022. 4:vdac140. doi: 10.1093/naojnl/vdac140
204. Reinhardt A, Pfister K, Schrimpf D, Stichel D, Sahm F, Reuss DE, Capper D, Wefers AK, Ebrahimi A, Sill M, Felsberg J, Reifenberger G, Becker A, Prinz M, Staszewski O, Hartmann C, Schittenhelm J, Gramatzki D, Weller M, Olar A, Rushing EJ, Bergmann M, Farrell MA, Blümcke I, Coras R, Beckervordersandforth J, Kim SH, Rogerio F, Dimova PS, Niehusmann P, Unterberg A, Platten M, Pfister SM, Wick W, Herold-Mende C, von Deimling A. Anaplastic ganglioglioma - a diagnosis comprising several distinct tumour types. **Neuropathol Appl Neurobiol** 2022. 17:e12847. doi: 10.1111/nan.12847
203. Epping L*, Schroeter CB*, Nelke C*, Bock S, Gola L, Ritter N, Herrmann AM, Räuber S, Henes A, Fernandez-Orth J, Neuhaus W, Bittner S, Budde T, Platten M, Kovac S, Seeböhm G, Ruck T, Cerina M, Meuth SG*. Activation of non-classical NMDA receptors by glycine impairs barrier function of brain endothelial cells. **Cell Mol Life Sci** 2022. 79:479. doi: 10.1007/s00018-022-04502-z
202. Hoyer C, Winzer S, Matthé E, Heinle I, Sandkci V, Nabavi D, Platten M, Puetz V, Szabo K. Current diagnosis and treatment practice of central retinal artery occlusion: results from a survey among German stroke units. **Neurol Res Pract** 2022. 4:30. doi: 10.1186/s42466-022-00193-w
201. Caramanna I, de Kort JM, Brandes AA, Taal W, Platten M, Idbaih A, Frenel JS, Wick W, Preetha CJ, Bendszus M, Vollmuth P, Reijneveld JC, Klein M. Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101. **Neuro-Oncol Pract** 2022. 9:310-6. doi: 10.1093/nop/npac022

200. Ratliff M, Kim H, Qi H, Azorin DD, Hausmann D, Khajuria RK, Ratliff T, Patel A, Maier E, Cousin L, Ogier A, Sahm F, Ertman N, Bunse L, Winkler F, El-Khoury V, Platten M, Kwon YJ. Patient-derived tumor organoids for the development of personalized drug therapies in recurrent glioblastoma. **Int J Mol Sci** 2022. 23:6572. doi: 10.3390/ijms23126572
199. Grassl N, Ebert AD, Szabo K, Aghazadeh Y, Platten M, Alonso A. Pearls and Oy-sters: Hemiballism and orbitofrontal-like syndrome in a patient with unilateral tuberothalamic stroke. **Neurology** 2022. 99:625-627. doi: 10.1212/WNL.0000000000201066
198. Wittayer M, Weber CE, Platten M, Schirmer L, Gass A, Eisele P. Spatial distribution of multiple sclerosis iron rim lesions and their impact on disability. **Mult Scler Relat Disord** 2022. 64:103967. doi: 10.1016/j.msard.2022.103967
197. Eisele P, Wittayer M, Weber CE, Platten M, Schirmer L, Gass A. Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions. **Mult Scler** 2022. 28:2294-2298. doi: 10.1177/13524585221106338
196. Kebir S, Lazaridis L, Wick W, Platten M, Tabatabai G, Combs SE, Schmidt T, Agkatsev S, Blau T, Mäurer I, Kahlert U, Sagerer A, Berberich A, Heider S, Muther M, Bodensohn R, Behling F. Gender disparity regarding work-life balance satisfaction among German neuro-oncologists: a YoungNOA survey. **Neuro-Oncol** 2022. 24(9):1609-1611. doi: 10.1093/neuonc/noac114
195. Wick A, Sander A, Koch M, Bendszus M, Combs S, Haut T, Dormann A, Walter S, Pertz M, Merkle-Lock J, Selkrig N, Limprecht R, Baumann L, Kieser M, Sahm F, Schlegel U, Winkler F, Platten M, Wick W, Kessler T. Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial. **BMC Cancer** 2022. 22:645. doi: 10.1186/s12885-022-09720-z
194. Bunse L, Rupp AK, Poschke I, Bunse T, Lindner K, Wick A, Blobner J, Misch M, Tabatabai G, Glas M, Schnell O, Gempt J, Denk M, Reifenger G, Bendszus M, Wuchter P, Steinbach JP, Wick W, Platten M. AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas. **Neurol Res Pract** 2022. 4:20. doi: 10.1186/s42466-022-00184-x
193. Sandikci V, Ebert A, Zurwesten L, Platten M, Szabo K, Hoyer C. The remains of the day: neuropsychological findings in postacute transient global amnesia. **J Neurol** 2022. 269:4764-4771. doi: 10.1007/s00415-022-11110-1
192. Wenzel N, Wittayer M, Weber CE, Schirmer L, Platten M, Gass A, Eisele P. MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions. **J Neurol** 2022. 269(8):4414-4420. doi: 10.1007/s00415-022-11082-2
191. Hoyer C, Schlenker J, Sandikci V, Ebert A, Wittayer M, Platten M, Szabo K. Sex-Specific Differences in Pre-Stroke Characteristics Reveal Vulnerability of Elderly Women. **J Pers Med** 2022. 12:344. doi: 10.3390/jpm12030344
190. Bunse L, Sommerer C, Tan CL, Korell F, Schmitt A, Hükelhoven-Krauss A, Neuber B, Mertens T, Platten M, Green EW, Zeier M, Schmitt M. Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV. **Int J Mol Sci** 2022. 23:1029. doi: 10.3390/ijms23031029
189. Fastner C, Szabo K, Samartzi M, Kruska M, Akin I, Platten M, Baumann S, Alonso A. Treatment standards for direct oral anticoagulants in patients with acute ischemic stroke and non-valvular atrial fibrillation: A survey among German stroke units. **PLoS One** 2022. 17:e0264122. doi: 10.1371/journal.pone.0264122
188. Wittayer M, Hoyer C, Roßmanith C, Platten M, Gass A, Szabo K. Hippocampal subfield involvement in patients with transient global amnesia. **J Neuroimaging** 2022. 32:264-267. doi: 10.1111/jon.12973
187. Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, Fernandes RA, Gomez AM, Nadj GS, Bartley CM, Schubert RD, Hawes IA, Vazquez SE, Iyer M, Zuchero JB, Teegen B, Dunn JE, Lock CB, Kipp LB, Cotham VC, Ueberheide BM, Aftab BT, Anderson MS, DeRisi JL, Wilson MR, Bashford-Rogers RJM, Platten M, Garcia KC, Steinman L, Robinson WH. Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GialCAM. **Nature** 2022. 603:321-327. doi: 10.1038/s41586-022-04432-7
186. Weber CE, Wittayer M, Kraemer M, Dabringhaus A, Bail K, Platten M, Schirmer L, Gass A, Eisele P. Long-term dynamics of multiple sclerosis iron rim lesions. **Mult Scler Relat Disord** 2022. 57:103340. doi: 10.1016/j.msard.2021.103340

185. Reichl M, Wittayer M, Weber CE, Platten M, Gass A, Eisele P. Consistency of the "central vein sign" in chronic multiple sclerosis lesions. **Mult Scler Relat Disord** 2022. 58:103530. doi: 10.1016/j.msard.2022.103530

2021

184. Grudzinski S, Heger S, de Jonge A, Schipp J, Dumont E, Larrat B, Schad L, Platten M, Fatar M. Simulation, Implementation and Measurement of Defined Sound Fields for Blood-Brain Barrier Opening in Rats. **Ultrasound Med Biol** 2021. 48:422-436. doi: 10.1016/j.ultrasmedbio.2021.10.003
183. Kilian M, Friedrich M, Sanghvi K, Green E, Pusch S, Kawauchi D, Löwer M, Sonner JK, Krämer C, Zaman J, Jung S, Breckwoldt MO, Willimsky G, Eichmüller SB, von Deimling A, Wick W, Sahm F, Platten M, Bunse L. T cell receptor therapy targeting mutant capicua transcriptional repressor in experimental gliomas. **Clin Cancer Res** 2021. 28:378-389. doi: 10.1158/1078-0432.CCR-21-1881
182. Maas SLN, Stichel D, Hielscher T, Sievers P, Berghoff AS, Schimpf D, Sill M, Euskirchen P, Blume C, Patel A, Dogan H, Reuss D, Dohmen H, Stein M, Reinhardt AK, Suwala AK, Wefers AK, Baumgarten P, Ricklefs F, Rushing EJ, Bewerunge-Hudler M, Ketter R, Schittenhelm J, Jaunmuktane Z, Leu S, Greenway FEA, Bridges LR, Jones T, Serrano GCJ, Golfinos J, Sen C, Mawrin C, Jungk C, Hänggi D, Westphal M, Lamszus K, Etminan N, Jungwirth G, MD, Herold-Mende C, Unterberg A, Harter PN, Wirsching HG, Neidert MC, Ratliff M, Platten M, Snuderl M, Aldape KD, Brandner S, Hench J, Frank S, Pfister SM, Jones DTW, Reifenberger G, Acker T, Wick W, Weller M, Preusser M, von Deimling A, Sahm F for the German Consortium on Aggressive Meningiomas (KAM). Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. **J Clin Oncol** 2021. 39:3839-3852. doi: 10.1200/JCO.21.00784
181. Blobner J, Kilian M, Tan CL, Aslan K, Sanghvi K, Meyer J, Fischer M, Jähne K, Breckwoldt MO, Sahm F, von Deimling A, Bendszus M, Wick W, Platten M, Green E, Bunse L. Comparative evaluation of T cell receptors in experimental glioma-draining lymph nodes. **Neuro-Oncol Adv** 2021. 3:vdab147. doi: 10.1093/noajnl/vdab147
180. Panitz V, Končarević S, Sadik A, Friedel D, Bausbacher T, Trump S, Farztdinov V, Schulz S, Sievers P, Schmidt S, Jürgenson I, Jung S, Kuhn K, Pflüger I, Sharma S, Wick A, Pfänder P, Selzer A, Vollmuth P, Sahm F, von Deimling A, Heiland I, Hopf C, Schulz-Knappe P, Pike I, Platten M, Wick W, Opitz CA. Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. **Theranostics** 2021. 11:9217-9233. doi: 10.7150/thno.60679
179. Weber CE, Krämer J, Wittayer M, Gregori J, Randoll S, Weiler F, Heldmann S, Roßmanith C, Platten M, Gass A, Eisele P. Association of iron rim lesions with brain and cervical cord volume in relapsing multiple sclerosis. **Eur Radiol** 2021. 32:2012-2022. doi: 10.1007/s00330-021-08233-w
178. Preetha CJ, Meredig H, Brugnara G, Mahmutoglu MA, Foltyn M, Isensee F, Kessler T, Pflüger I, Schell M, Neuberger U, Petersen J, Wick A, Heiland S, Prof. Debus J, Platten M, Idbaih A, Brandes AA, Winkler F, van den Bent MJ, Nabors B, Stupp R, Maier-Hein K, Gorlia T, Tonn JC, Weller M, Wick W, Bendszus M, Vollmuth P. Deep-learning based synthesis of post-contrast T1-weighted magnetic resonance imaging for tumor response assessment in neuro-oncology: a multicenter, retrospective study. **Lancet Digital Health** 2021. 3:e784-e794. doi: 10.1016/S2589-7500(21)00205-3
177. Friedrich M, Kehl N, Engelke N, Kraus J, Lindner K, Münch P, Groden C, Gass A, Etminan N, Fatar M, von Deimling A, Reuss D, Platten M, Bunse L. Intrathecal activation of CD8+ memory T cells in IgG4-related disease of the brain parenchyma. **EMBO Mol Med** 2021. e13953. doi: 10.15252/emmm.202113953
176. Hoyer C, Higashida K, Fabbian F, De Giorgi A, Sandikci V, Ebert A, Platten M, Okazaki S, Manfredini R, Szabo K. Chronobiology of transient global amnesia. **J Neurol** 2021. 269:361-367. doi: 10.1007/s00415-021-10639-x
175. Sandikci V, Ebert A, Hoyer C, Platten M, Szabo. Impaired semantic memory during acute transient global amnesia. **J Neuropsychol** 2021. 16:149-160. doi: 10.1111/jnp.12251
174. Eisele P, Kraemer M, Dabringhaus A, Weber CE, Ebert A, Platten M, Schad LR, Gass A. Characterization of chronic active multiple sclerosis lesions with sodium (²³Na) MRI. **Eur J Neurol** 2021. 28:2392-2395. doi: 10.1111/ene.14873
173. Hoyer C, Ebert A, Sandikci V, Platten M, Szabo. Sex-related differences in stressful events precipitating transient global amnesia – a retrospective observational study. **J Neurol Sci** 2021. 425:117464. doi: 10.1016/j.jns.2021.117464

172. Zhang XW, Huck K, Jähne K, Cichon F, Sonner JK, Ufer F, Bauer S, Woo MS, Green E, Lu K, Kilian M, Friese MA, Platten M, Sahm K. Activity-regulated cytoskeleton-associated protein/activity-regulated gene 4.1 (Arc/Arg4.1) enhances dendritic cell vaccination in experimental melanoma. **Oncoimmunol** 2021. 10:1920739. doi: 10.1080/2162402X.2021.1920739
171. Weber CE, Wittayer M, Kraemer M, Dabringhaus A, Platten M, Gass A, Eisele P. Quantitative MRI texture analysis in chronic active multiple sclerosis lesions. **J Magn Reson Imag** 2021. 79:97-102. doi: 10.1016/j.mri.2021.03.016
170. Kleinsorge MT, Ebert A, Förster A, Weber CE, Roßmanith C, Platten M, Gass A, Eisele P. MRI topography of lesions related to internuclear ophthalmoplegia in patients with multiple sclerosis or ischemic stroke. **J Neuroimaging** 2021. 31:471-474. doi: 10.1111/jon.12847
169. Friedrich M*, Sankowski R*, Bunse L*, Green E, Kilian M, Green E, Ramallo-Guevara C, Pusch S, Poschet G, Sanghvi K, Hahn M, Bunse T, Münch P, Sonner JK, von Landenberg A, Cichon F, Aslan K, Trobisch T, Schirmer L, Abu-Sammour D, Kessler T, Ratliff M, Schrimpf D, Sahm F, Hopf C, Heiland DH, Schnell O, Beck J, Böttcher C, Fernandez-Zapata C, Priller J, Heiland S, Gutcher I, Quintana F, von Deimling A, Wick W, Prinz M* and Platten M*. Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. **Nat Cancer** 2021. 2:723–740. doi: 10.1038/s43018-021-00201-z
168. Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, Green E, Justesen S, Behrens G, Breckwoldt M, Freitag A, Rother LM, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Stevanovic S, Tabatabai G, Steinbach JP, Bendszus M, von Deimling A, Schmitt M, Wick W. A vaccine targeting mutant IDH1 in newly diagnosed glioma. **Nature** 2021. 592:463-468. doi: 10.1038/s41586-021-03363-z
167. Mohapatra SR, Sadik A, Sharma S, Poschet G, Gegner HM, Lanz TV, Lucarelli P, Klingmüller U, Platten M, Heiland I, Opitz CA. Hypoxia Routes Tryptophan Homeostasis Towards Increased Tryptamine Production. **Front Immunol** 2021. 12:590532. doi: 10.3389/fimmu.2021.590532
166. Grassl N, Baumann S, Kruska M, Fatar M, Akin I, Platten M, Borggreffe M, Alonso A, Szabo K, Fastner C. Acute ischemic stroke and elevated troponin: Diagnostic work-up and therapeutic consequences. **Deut Med Wochenschr** 2021. 146:534-541. doi: 10.1055/a-1308-7490
165. Hoyer C, Kahlert C, Güney R, Schlichtenbrede F, Platten M, Szabo K. Central retinal occlusion as a neuro-ophthalmological emergency: The need for raising public awareness. **Eur J Neurol** 2021. 28:2111-2114. doi: 10.1111/ene.14735
164. Weber CE, Nagel K, Ebert A, Roßmanith C, Adlung A, Platten M, Schad LR, Gass A, Eisele P. Diffusely appearing white matter in multiple sclerosis: insights from sodium (²³Na) MRI. **Mult Scler Relat Disord** 2021. 49:102752. doi: 10.1016/j.msard.2021.102752
163. Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss DE, Blattner-Johnson M, Worst B, Heilig C, Beck K, Horak P, Kreutzfeldt S, Paff E, Stark S, Johann P, Selt F, Ecker J, Sturm D, Reinhard AK, Wefers AK, Sievers P, Ebrahimi A, Suwala A, Fernández-Klett F, Casalini B, Korshunov A, Hovestadt V, Kommos FKF, Kriegsmann M, Schick M, Bewerunge-Hudler M, Milde T, Witt O, Kulozik AE, Kool M, Romero-Perez L, Grünwald TGP, Kirchner T, Wick W, Platten M, Unterberg A, Uhl M, Abdollahi A, Debus J, Lehner B, Thomas C, Hasselblatt M, Paulus W, Hartmann C, Staszewski O, Prinz M, Hench J, Frank S, Versleijen-Jonkers YMH, Weidema ME, Mentzel T, Griewank K, Idoate Gastearena MAI, Chang KTE, Low SYY, Cuevas-Bourdier A, Mittelbronn M, Mynarek M, Rutkowski S, Schüller U, Mautner VF, Schittenhelm J, Serrano J, Snuderl M, Büttner R, Klingebiel T, Buslei R, Gessler M, Wesseling P, Dinjens WNM, Brandner S, Schirmacher P, Stenzinger A, Brors B, Glimm H, Heining C, Tirado OM, Sáinz-Jaspeado M, Mora J, Alonso J, Garcia del Muro X, Moran S, Esteller M, Benhamida JK, Ladanyi M, Wardelmann E, Antonescu C, Flanagan A, Dirksen U, Baumhoer D, Hartmann W, Vokuhl C, Mechttersheimer G, Flucke U, Petersen I, Capper D, Jones DTW, Fröhling S, Pfister SM, von Deimling A. Sarcoma classification by DNA-methylation profiling. **Nat Commun** 2021. 12:498. doi: 10.1038/s41467-020-20603-4
162. Weber CE, Kraemer M, Dabringhaus A, Ebert A, Platten M, Gass A, Eisele P. Venous diameter changes in chronic active multiple sclerosis lesions. **J Neuroimaging** 2021. 31:394-400. doi: 10.1111/jon.12818
161. Hoyer C, Ebert A, Szabo K, Platten M, Meyer-Lindenberg A, Kranaster L. Decreased utilization of mental health emergency service during the COVID-19 pandemic. **Eur Arch Psychiatry Clin Neurosci** 2021. 271:377-379. doi: 10.1007/s00406-020-01151-w
160. Costa B, Fletcher M, Boskovic P, Ivanova EL, Eisemann T, Lohr S, Bunse L, Löwer M, Burchard S, Korshunov A, Liu HK, Platten M, Radlwimmer B, Angel P, Peterziel H. A set of cell lines derived from a genetic murine glioblastoma model recapitulates molecular and morphological characteristics of human tumor. **Cancers** 2021. 13:230. doi: 10.3390/cancers13020230

2020

159. Hahn A, Bode J, Alexander A, Krüwel T, Karimian-Jazi K, Sommerkamp A, Schwarz D, Abdollahi A, Wick W, Platten M, Bendszus M, Tews B, Kurz FT, Breckwoldt MO. Large-scale characterization of microvasculature geometry in development and disease by tissue clearing and quantitative ultramicroscopy. **J Cereb Blood Flow Metab** 2020. 41:1536-1546. doi: 10.1177/0271678X20961854
158. Hoyer C, Weber C, Sandikci V, Ebert A, Platten M, Szabo K. Decreased admissions and change in arrival mode in patients with cerebrovascular events during the first surge of the COVID-19 pandemic. **Neurol Res Pract** 2020. 2:47. doi: 10.1186/s42466-020-00094-w
157. Hoyer C, Grassl N, Bail K, Stein P, Ebert A, Platten M, Szabo K. Changes of demographic and diagnostic spectra in emergency department patients presenting with neurological symptoms during the COVID-19 pandemic: A retrospective Cohort Study. **Neuropsychiatr Dis Treat** 2020. 16:2221-2227. doi: 10.2147/NDT.S273913
156. Lercher A, Popa A, Kosack L, Viczenczova C, Klavins K, Lanz TV, Platten M, Bergthaler A. Type I interferon reprograms hepatocyte metabolism and reveals novel compensatory mechanism of the tryptophan-kynurenine pathway in viral hepatitis. **PLoS Pathog** 2020. 16:e1008973. doi: 10.1371/journal.ppat.100897
155. Kessler T, Berberich A, Sadik A, Sahm F, Gorlia T, Meisner C, Hoffmann D, Wick A, Kickingereder P, Rübmann P, Bendszus M, Opitz C, Weller M, van den Bent M, Stupp R, Golinopoulos V, Winkler F, Brandes AA, von Deimling A, Platten M, Wick W. Methylome analysis of three glioblastoma cohorts reveals chemotherapy sensitivity markers within DDR genes. **Cancer Med** 2020. 9:8373-8385. doi: 10.1002/cam4.3447
154. Weber CE, Ebert A, Platten M, Gass A, Eisele P. Susceptibility-Weighted 3T MRI of the Swallow Tail Sign in Multiple Sclerosis: A Case Control Study. **J Neuroimaging** 2020. 30(6):766-768. doi: 10.1111/jon.12775
153. Kickingereder P, Brugnara G, Hansen MB, Nowosielski M, Pflüger I, Schell M, Isensee F, Foltyn M, Neuberger U, Kessler T, Sahm F, Wick A, Heiland S, Weller M, Platten M, von Deimling A, Maier-Hein KH, Østergaard L, van den Bent MJ, Gorlia T, Wick W, Bendszus M. Noninvasive characterization of tumor angiogenesis and oxygenation in bevacizumab-treated recurrent glioblastoma using dynamic susceptibility MRI: post-hoc analysis of the EORTC-26101 trial. **Radiology** 2020. 297:164-175. doi: 10.1148/radiol.2020200978
152. Weber CE, Sandikci V, Ebert A, Szabo K, Platten M, Gass A, Eisele P. Investigation of the “central vein sign” in infratentorial multiple sclerosis lesions. **Mult Scler Relat Disord** 2020. 45:102409. doi: 10.1016/j.msard.2020.102409
151. Grassl N, Bunse L, Beutel T, Klockziem M, Bunse L, Gass A, Platten M, Eisele P. Nivolumab for Treatment of Progressive Multifocal Leukoencephalopathy in Sézary Syndrome. **Eur J Neurol** 2020. 27:2373-2374. doi: 10.1111/ene.14433
150. Berberich A, Bartels F, Tang Z, Pusch S, Hücke N, Kessler T, Dong Z, Wiestler B, Winkler F, Platten M, Wick W, Abdollahi A, Lemke D. LAPTM5 – CD40 crosstalk in glioblastoma invasion and temozolomide resistance. **Front Oncol** 2020. 10:747. doi: 10.3389/fonc.2020.00747
149. Szabo K, Hoyer C, Caplan LR, Grassl R, Griebel M, Ebert A, Platten M, Gass A. Diffusion-weighted MRI characteristics in transient global amnesia and their diagnostic implications. **Neurology** 2020. 95:e206-e212. doi: 10.1212/WNL.00000000000009783
148. Hoyer C, Ebert A, Huttner H, Puetz V, Kallmünzer B, Barlinn K, Harloff A, Haverkamp C, Weiller C, Platten M, Szabo K. Acute. **Stroke** 2020. in Times of the COVID-19 Pandemic: A Multicenter Study. **Stroke** 51:2224-2227. doi: 10.1161/STROKEAHA.120.030395
147. van Tilburg CM, Witt R, Heiss M, Pajtler KW, Plass C, Poschke I, Platten M, Harting I, Sedlacek O, Freitag A, Meyrath D, Taylor L, Balasubramanian GP, Jäger N, Pfaff E, Worst B, Milde T, Pfister SM, Jones DTW, Kopp-Schneider A, Witt O. INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. **BMC Cancer** 2020. 20:523. doi: 10.1186/s12885-020-07008-8
146. Hoyer C, Ebert A, Pooyeh A, Eisele P, Gass A, Platten M, Szabo K. Shedding light on the clinical recognition process of transient global amnesia. **Eur J Neurol** 2020. 27:1821-1824. doi: 10.1111/ene.14371
145. Kudo T, Prentzell T, Mohapatra S, Sahm F, Zhao Z, Grummt I, Opitz CA, Platten M, Green E. Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBP β . **Front Immunol** 2020. 11:657. doi: 10.3389/fimmu.2020.00657

144. Hoyer C, Stein P, Ebert A, Rausch HW, Nagel S, Eisele P, Alonso A, Platten M, Szabo K. Comparing Expert and Non-Expert Assessment of Patients Presenting with Neurological Symptoms to the Emergency Department: A Retrospective Observational Study. **Neuropsychiatr Dis Treat** 2020. 16:447-456. doi: 10.2147/NDT.S236160
143. Kessler T, Berberich A, Casalini B, Druschler K, Störch H, Dormann A, Walter S, Hai L, Schlesner M, Herold-Mende C, Bendszus M, Sahm K, von Deimling A, Winkler F, Platten M, Wick W, Sahm F, Wick A. Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. **Neuro-Oncol Adv** 2020. 2:vdz060. doi: 10.1093/oaajnl/vdz060
142. Schell M, Pflüger I, Brugnara G, Isensee F, Neuberger U, Foltyn M, Kessler T, Sahm F, Wick A, Nowosielski M, Heiland S, Weller M, Platten M, Maier-Hein KH, von Deimling A, van den Bent MJ, Gorlia T, Wick W, Bendszus M, Kickingeder P. Validation of Diffusion MRI Phenotypes for Predicting Response to Bevacizumab in Recurrent Glioblastoma: Post-Hoc Analysis of the EORTC-26101 Trial. **Neuro-Oncol** 2020. 22:1667-1676. doi: 10.1093/neuonc/noaa120
141. Aslan K, Turco V, Blobner J, Sonner JK, Liuzzi AR, Núñez NG, De Feo D, Kickingeder P, Fischer M, Green E, Sadik A, Friedrich M, Sanghvi K, Kilian M, Cichon F, Wolf L, Jähne K, von Landenberg A, Bunse L, Sahm F, Schrimpf D, Meyer J, Alexander A, Brugnara G, Röth R, Pflöderer K, Niesler B, von Deimling A, Opitz CA, Breckwoldt MO, Heiland S, Bendszus M, Wick W, Becher B, Platten M. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. **Nat Commun** 2020. 11:931. doi: 10.1038/s41467-020-14642-0
140. Wick A, Kessler T, Platten M, Meisner C, Bamberg Herrlinger U, Felsberg J, Weyerbrock A, Seidel C, Steinbach JP, Sabel M, Vesper J, Debus J, Sahm F, Meixensberger J, Ketter R, Mayer-Steinacker R, von Deimling A, Reifenberger G, Weller M, Wick W for the NOA-08 Study Group of the Neurooncology Working Group (NOA) of the German Cancer Society. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter-methylated malignant astrocytoma. **Neuro-Oncol** 2020. 22:1162-1172. doi: 10.1093/neuonc/noaa033
139. Karimian-Jazi K, Münch P, Alexander A, Fischer M, Piechutta M, Karreman MA, Solecki G, Berghoff AS, Pflöderer K, Friedrich M, Deumelandt K, Kurz FT, Wick W, Heiland S, Bendszus M, Winkler F, Platten M, Breckwoldt MO. Monitoring innate immune cell dynamics in the glioma microenvironment by magnetic resonance imaging and multiphoton microscopy (MR-MPM). **Theranostics** 2020. 10:1873-1883. doi: 10.7150/thno.38659
138. Berberich A, Schmitt LM, Pusch S, Hielscher T, Rübmann P, Hucke N, Latzer P, Heßling B, Lemke D, Kessler T, Platten M, Wick W. cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma. **J Neurooncol** 2020. 146:9-23. doi: 10.1007/s11060-019-03348-z
137. Paech D, Kuder TA, Roßmanith C, Griebel M, Eisele P, Platten M, Ladd ME, Schlemmer HP, Gass A, Szabo K. What remains after transient global amnesia (TGA)? An ultra-high field 7T magnetic resonance imaging of the hippocampus. **Eur J Neurol** 2020. 27:406-409. doi: 10.1111/ene.14099
136. Anssar T, Leitzmann M, Linker R, Meier C, Becker C, Jick S, Sahm K, Platten M, Hau P, Seliger C. Autoimmune diseases and immunosuppressive therapy in relation to risk of glioma. **Cancer Med** 2020. 9:1263-1275. doi: 10.1002/cam4.2767

2019

135. Hoyer C, Stein P, Rausch HW, Alonso A, Nagel S, Platten M, Szabo K. The use of a dedicated neurological triage system improves process times and resource utilization: a prospective observational study from an interdisciplinary emergency department. **Neurol Res Pract** 2019. 1:29. doi: 10.1186/s42466-019-0036-y
134. Hoyer C, Stein P, Alonso A, Platten M, Szabo K. Uncompleted emergency department care and discharge against medical advice in patients with neurological complaints: a chart review. **BMC Emergency Medicine** 2019. 19:52. doi: 10.1186/s12873-019-0273-y
133. Eisele P, Fischer K, Szabo K, Platten M, Gass A. Characterization of contrast-enhancing and non contrast-enhancing Multiple Sclerosis lesions with susceptibility-weighted imaging. **Front Neurol** 2019. 10:1082. doi: 10.3389/fneur.2019.01082

132. Reinhardt AK, Stichel D, Schrimpf D, Korshunov A, Sahm F, Reuss DE, Koelsche C, Huang K, Wefers AK, Weller M, Gramatzki D, Felsberg J, Reifenberger G, Becker A, Hans VH, Prinz M, Staszewski O, Acker T, Dohmen H, Hartmann C, Paulus W, Heß K, Brokinkel B, Schittenhelm J, Buslei R, Deckert M, Mawrin C, Hewer E, Poh U, Jaunmuktane Z, Brandner S, Unterberg A, Hänggi D, Platten M, Pfister SM, Wick W, Herold-Mende C, Jones DTW, Capper D, von Deimling A. Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. **Acta Neuropathol Com** 2019. 7:163. doi: 10.1186/s40478-019-0801-8
131. Sonner JK*, Keil M*, Falk-Paulsen M*, Mishra N, Rehman A, Kramer M, Deumelandt K, Röwe J, Sanghvi K, Wolf L, von Landenberg A, Wolff H, Bharti R, Oezen I, Lanz TV, Wanke F, Tang Y, Brandao I, Mohapatra S, Epping L, Grill A, Röth R, Niesler B, Meuth SG, Opitz CA, Okun JG, Reinhardt C, Kurschus F, Wick W, Bode HB, Rosenstiel P*, Platten M*. Dietary tryptophan links encephalitogenicity of autoreactive T cells with gut microbial ecology. **Nat Commun** 2019. 10:4877. doi: 10.1038/s41467-019-12776-4
130. Eisele P, Noor L, Baumann S, El-Battrawy I, Ebert A, Gass A, Akin I, Platten M, Szabo K. Interaction between the heart and the brain in transient global amnesia. **J Neurol** 2019. 266:3048-3057. doi: 10.1007/s00415-019-09529-0
129. Alonso A, Etminan N, Krebs J, Szabo K, Platten M, Foerster A. Fulminant cytotoxic edema in a patient with pneumococcal meningoencephalitis. **J Clin Neurol** 2019. 15:575-577. doi: 10.3988/jcn.2019.15.4.575
128. Nowosielski M, Gorlia T, Bromberg J, Sahm F, Harting I, Kickingereder P, Brandes AA, Taphoorn M, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Weller M, Fabbro M, Dubois F, Platten M, Golfopoulos V, van den Bent MJ, Bendszus M, Wick W. Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. **Neurology** 2019. 92:e2754-e2763. doi: 10.1212/WNL.0000000000007643
127. Kickingereder P, Isensee F, Tursunova I, Petersen J, Neuberger U, Bonekamp D, Brugnara G, Schell M, Kessler T, Foltyn M, Harting I, Sahm F, Prager M, Nowosielski M, Wick A, Nolden M, Radbruch A, Debus J, Schlemmer HP, Heiland S, Platten M, von Deimling A, van den Bent MJ, Gorlia T, Wick W, Bendszus M, Maier-Hein KH. Automated quantitative tumor response assessment of MRI in neuro-oncology with artificial neural networks. **Lancet Oncol** 2019. 20:728-740. doi: 10.1016/S1470-2045(19)30098-1
126. Schwarz D, Niederle T, Münch P, Hielscher T, Hassel JC, Schlemmer HP, Platten M, Winkler F, Wick W, Heiland S, Delorme S, Bendszus M, Bäumer P, Breckwoldt MO. Susceptibility weighted imaging in malignant melanoma brain metastasis. **J Magn Reson Imaging** 2019. 50:1251-1259. doi: 10.1002/jmri.26692
125. Breckwoldt MO, Bode J, Sahm F, Krüwel T, Solecki G, Hahn A, Wirthschaft P, Berghoff AS, Haas M, Venkataramani V, von Deimling A, Wick W, Herold-Mende C, Heiland S, Platten M, Bendszus M, Kurz FT, Winkler F, Tews B. Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease. **Front Neurosci** 2019. 12:1004. doi: 10.3389/fnins.2018.01004
124. Eisele P, Szabo K, Ebert A, Radbruch A, Platten M, Schoenberg SO, Gass A. Diffusion-weighted imaging of the dentate nucleus after repeated application of gadolinium-based contrast agents in multiple sclerosis. **Magn Reson Imaging** 2019. 58:1-5. doi: 10.1016/j.mri.2019.01.007
123. Hoffmann A, Pfeil J, Mueller AK, Helluy X, Cuihua W, Heiland S, Platten M, Chen JW, Bendszus M, Breckwoldt MO. MRI of Iron Oxide Nanoparticles and Myeloperoxidase Activity Links Inflammation to Brain Edema in Experimental Cerebral Malaria. **Radiology** 2019. 290:359-367. doi: 10.1148/radiol.2018181051
122. Eisele P, Konstandin S, Szabo K, Ebert A, Roßmanith C, Kerschensteiner M, Platten M, Schoenberg SO, Schad LR, Gass A. Temporal evolution of acute multiple sclerosis lesions on sodium (23Na) MRI. **Mult Scler Relat Disord** 2019. 29:48-54. doi: 10.1016/j.msard.2019.01.027
121. Berberich A, Pusch S, Hielscher T, Oezen I, Thome C, Schmitt L, Ciprut S, Ruebmann P, Hücke N, Lemke D, Kessler T, Platten M, Wick W. Targeting resistance against the MDM2 inhibitor RG7388 in glioblastoma cells by MEK inhibitor trametinib. **Clin Cancer Res** 2019. 25:253-265. doi: 10.1158/1078-0432.CCR-18-1580
120. Wolf ME, Rausch HW, Eisele P, Habich S, Platten M, Alonso A. Acute Corticonuclear Tract Ischemic Stroke with Isolated Central Facial Palsy. **J Stroke Cerebrovasc Dis** 2019. 28:495-498. doi: 10.1016/j.jstrokecerebrovasdis.2018.10.030
119. Eisele P, Szabo K, Ebert A, Platten M, Gass A. Brain Atrophy in Natalizumab-treated Patients with Multiple Sclerosis: A 5-year Retrospective Study. **J Neuroimaging** 2019. 29:190-192. doi: 10.1111/jon.12586

118. Hilf N*, Kuttruff-Coqui S*, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, von der Burg SH, thor Straten P, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep J, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten C, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Stockhausen M, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brueck A, Ludwig J, Schoor O, Tadmor A, Green EW, Fritsche J, Meyer M, Pawlowski N, Dörner S, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh H, Sahin U, Dietrich PY, Wick W. Actively personalized vaccination trial for newly diagnosed glioblastoma. **Nature** 2019. 566(7745):E13. doi: 10.1038/s41586-019-0959-z
117. Wick W, Dettmer S, Berberich A, Kessler T, Schenkel I, Wick A, Pfaff E, Brors B, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Eisenmenger A, von Deimling A, Jones DTW, Pfister SM, Sahm F, Platten M. Phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation: NCT Neuro Master Match (N²M²) – the NOA-20 trial. **Neuro-Oncol** 2019. 21:95-105. doi: 10.1093/neuonc/noy161

2018

116. Adam I, Dewi DL, Mohapatra SR, Mooiweer J, Sadik A, Berdel B, Keil M, Sonner JK, Thedieck K, Rose AJ, Platten M, Heiland I, Trump S, Opitz CA. Upregulation of tryptophanyl-tRNA synthetase adapts human cancer cells to nutritional stress caused by tryptophan degradation. **Oncoimmunology** 2018. 7(12):e1486353. doi: 10.1080/2162402X.2018.1486353
115. Berberich A, Hielscher T, Kickingereder P, Druschler K, Riedemann L, Arzt M, Platten M, von Deimling A, Wick W, Sahm F, Bendszus M, Wick A. Non-measurable speckled contrast-enhancing lesions appearing during course of disease are associated with IDH mutation in high-grade glioma patients. **Int J Radiat Oncol Biol Phys** 2018. 102(5):1472-1480. doi: 10.1016/j.ijrobp.2018.07.2004
114. Bunse L*, Pusch S*, Bunse T*, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger M, Harter P, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende CM, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suva M, Niemeyer BA, von Deimling A, Wick W, Platten M. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. **Nat Med** 2018. 24:1192-1203. doi: 10.1038/s41591-018-0095-6
113. Capper D, Stichel D, Sahm F, Jones DTW, Schrimpf D, Sill M, Schmid S, Hovestadt V, Reuss DE, Koelsche C, Reinhardt AK, Wefers AK, Huang K, Sievers P, Ebrahimi A, Schöler A, Teichmann D, Koch A, Hänggi D, Unterberg A, Platten M, Wick W, Witt O, Milde T, Korshunov A, Pfister SM, von Deimling A. Practical implementation of DNA methylation and copy number-based CNS tumor diagnostics: The Heidelberg experience. **Acta Neuropathol** 2018. 136:181-210. doi: 10.1007/s00401-018-1879-y
112. Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F, Kölsche C, Wefers A, Reinhardt AK, Huang K, Sievers P, Shimizu H, Sasajima T, Oda M, Takahashi M, Nanjo H, Kobayashi Y, Miyake Y, Miyake Y, Adachi JI, Mishima K, Sasaki A, Nishikawa R, Bewerunge-Hudler M, Ryzhova M, Absalyamova O, Golanov A, Sinn P, Platten M, Jungk C, Winkler F, Wick A, Hänggi D, Unterberg A, Pfister S, Jones DTW, van den Bent M, Hegi M, French P, Gorlia T, Weller M, Capper D, Korshunov A, Herold-Mende C, Wick W, Louis DN, von Deimling A. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. **Acta Neuropathol** 2018. 136:153-166. doi: 10.1007/s00401-018-1849-4
111. Yamauchi Y, Safi S, Blattner C, Rathinasamy A, Umansky L, Warth A, Eichhorn M, Muley T, Herth FJF, Dienemann H, Platten M, Beckhove P, Utikal J, Hoffmann H, Umansky V. Circulating and tumor-infiltrating myeloid-derived suppressor cells in resectable non-small-cell lung cancer. **Am J Respi Crit Care Med** 2018. 198:777-787. doi: 10.1164/rccm.201708-1707OC

110. Reinhardt AK, Stichel D, Schrimpf D, Sahm F, Korshunov A, Reuss DE, Koelsche C, Huang K, Wefers AK, Hovestadt V, Sill M, Gramatzki D, Felsberg J, Reifemberger G, Koch A, Thomale UW, Becker A, Hans V, Prinz M, Staszewski O, Acker T, Dohmen-Scheufler H, Hartmann C, Mueller W, Tuffaha MSA, Paulus W, Heß K, Brokinkel B, Schittenhelm J, Monoranu CM, Kessler AK, Loehr M, Buslei R, Deckert M, Mawrin C, Kohlhof P, Hewer E, Olar A, Rodriguez F, Giannini C, Nageswara-Rao AA, Tabori U, Nunes NM, Weller M, Pohl U, Jaunmuktane Z, Brandner S, Unterberg A, Hänggi D, Platten M, Pfister SM, Wick W, Herold-Mende C, Jones D, von Deimling A, Capper D. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. **Acta Neuropathol** 2018. 136:273-291. doi: 10.1007/s00401-018-1837-8
109. Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuß D, Kratz A, Wefers AK, Huang K, Pajtl K, Schweizer L, Stichel D, Olar A, Engel N, Lindenberg K, Harter P, Braczynski A, Dohmen H, Garvalov BK, Coras R, Hölsken A, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschoner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez F, Acker T, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Hench J, Frank S, Serrano J, Kannan K, Tsigos A, Brück W, Hofer A, Brehmer S, Seitz-Rosenhagen M, Hänggi D, Hans V, Rozsnoki S, Hansford J, Kohlhof P, Kristensen B, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvett A, Keohane C, Mühleisen H, Mueller W, Pohl U, Prinz M, Zapatka M, Gottardo N, Monoranu CM, Perry A, Jones C, Jacques T, Radlwimmer B, Gessi M, Pietsch T, Reifemberger G, Wesseling P, Weller M, Collins VP, Blümcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott PA, Paulus W, Gajjar A, Robinson G, Taylor MD, Jaunmuktane Z, Ryzhova M, Platten M, Unterberg A, Wick W, Karajannis M, Mittelbronn M, Acker T, Hartmann C, Aldape K, Schüller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison D, Hasselblatt M, Snuderl M, Brandner S, Korshunov A, von Deimling A, Pfister SM. DNA methylation-based classification of central nervous system tumours. **Nature** 2018. 555:469-474. doi: 10.1038/nature26000
108. Blaes J, Thomé CM, Pfenning PN, Rübmann P, Sahm F, Wick A, Bunse T, Schmenger T, Sykora J, von Deimling A, Wiestler B, Merz C, Jugold M, Haberkorn U, Abdollahi A, Debus J, Gieffers C, Kunz C, Bendszus M, Kluge M, Platten M, Fricke H, Wick W, Lemke D. Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma. **Mol Cancer Res** 2018. 16:767-776. doi: 10.1158/1541-7786.MCR-17-0563
107. Eisele P, Szabo K, Ebert A, Platten M, Gass A. Spatiotemporal evolution of venous narrowing in acute multiple sclerosis lesions. **Neurol Neuroimmunol Neuroinflamm** 2018. 5:e440. doi: 10.1212/NXI.0000000000000440
106. Eisele P, Szabo K, Alonso A, Ong M, Platten M, Schönberg S, Gass A. Lack of T1 hyperintensity in the dentate nucleus after 15 administrations of a macrocyclic contrast agent in multiple sclerosis. **J Neurol Neurosurg Psychiatr** 2018. 89:324-326. doi: 10.1136/jnnp-2017-316102
105. Pfaff E, Kessler T, Balasubramanian P, Hertenstein A, Schrimpf D, Wick A, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Capper D, Schenkel I, Eisenmenger A, Brors B, Dettmer S, Platten M, Pfister SM, von Deimling A, Jones DTW, Wick W, Sahm F. Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter-hypermethylation – the NCT Neuro Master Match (N2M2) pilot study. **Neuro-Oncol** 2018. 20:826-837. doi: 10.1093/neuonc/nox216
104. Nowosielski M, Ellingson BM, Chinot OL, Garcia J, Revil C, Radbruch A, Nishikawa R, Mason WP, Henriksson R, Saran F, Kickingeder P, Platten M, Sandmann T, Abrey LE, Cloughesy TF, Bendszus M, Wick W. Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio. **Neuro-Oncol** 2018. 20:557-566. doi: 10.1093/neuonc/nox162
103. Kessler T, Sahm F, Sadik A, Hertenstein A, Reifemberger G, Tabatabai G, Steinbach J, Sure U, Krex D, Grosu A, Bendszus M, von Deimling A, Platten M, Wick W. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. **Neuro-Oncol** 2018. 20:367-379. doi: 10.1093/neuonc/nox160
102. Schwarzbach C, Ebert A, Hennerici MG, Platten M, Fatar M. Off-label use of IV t-PA in patients with intracranial neoplasm and cavernoma. **Ther Adv Neurol Disord** 2018. 11:1756285617753423. doi: 10.1177/1756285617753423
101. Rabe JH, Sammour DA, Schulz S, Munteanu B, Ott M, Ochs K, Hohenberger P, Marx A, Platten M, Opitz CA, Ory DS, Hopf C. Fourier Transform Infrared Microscopy Enables Guidance of Automated Mass Spectrometry Imaging to Predefined Tissue Morphologies. **Sci Rep** 2018. 8:313, corr:8:6361. doi: 10.1038/s41598-018-24807-z

2017

100. Costa da Silva M, Breckwoldt MO, Correia MP, Stojanovic A, Thielmann CM, Meister M, Muley T, Warth A, Vichi F, Platten M, Hentze MW, Cerwenka A, Muckenthaler MU. Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages. **Front Immunol** 2017. 8:1479. doi: 10.3389/fimmu.2017.01479
99. Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idhah A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfopoulos V, Bromberg JC, Platten M, Klein M, van den Bent M. Lomustine and Bevacizumab in Progressive Glioblastoma. **New Engl J Med** 2017. 377:1954-1963. doi: 10.1056/NEJMoa1707358
98. Ochs K, Ott M, Bunse T, Sahm F, Bunse L, Deumelandt K, Sonner JK, Keil M, von Deimling A, Wick W, Platten M. K27M-mutant histone-3 as a novel target for glioma immunotherapy. **Oncoimmunology** 2017. 6:e1328340. doi: 10.1080/2162402X.2017.1328340
97. Hoyer C, Alonso A, Schlotter-Weigel B, Platten M, Fatar M. HIV-associated cerebellar dysfunction and improvement with aminopyridine therapy: A case report. **Case Rep Neurol** 2017. 9:121-126. doi: 10.1159/000475544
96. Jung E, Osswald M, Blaes J, Wiestler B, Sahm F, Schmenger T, Solecki G, Deumelandt K, Kurz F, Xie R, Weil S, Heil O, Thomé C, Gömmel M, Syed M, Häring P, Huber P, Heiland S, von Deimling A, Platten M, Wick W, Winkler F. Tweety-homologue 1 drives brain colonization of gliomas. **J Neurosci** 2017. 37:6837-6850. doi: 10.1523/JNEUROSCI.3532-16.2017
95. Schulte K, Green E, Platten M, Daumke O. Structural basis for aryl hydrocarbon receptor-mediated gene activation. **Structure** 2017. 25:1025-1033.e3. doi: 10.1016/j.str.2017.05.008
94. Lanz TV, Becker S, Mohapatra S, Opitz C, Wick W, Platten M. Suppression of Th1 differentiation by tryptophan supplementation in vivo. **Amino Acids** 2017. 49:1169-1175. doi: 10.1007/s00726-017-2415-4
93. Tykocinski LO, Lauffer AM, Bohnen A, Krienke S, Tretter T, Adam A, Mohapatra SR, Saikali P, Löhning M, Neidhart M, Gay S, Oezen I, Platten M, Opitz CA, Lorenz HM. Synovial Fibroblasts Selectively Suppress Th1 Cell Responses through IDO1-Mediated Tryptophan Catabolism. **J Immunol** 2017. 198:3109-3117. doi: 10.4049/jimmunol.1600600
92. Pusch S, Krausert S, Fischer V, Balss J, Ott M, Schrimpf D, Eisel J, Beck AC, Jugold M, Eichwald V, Kaulfuss S, Zimmermann K, Pankin O, Rehwinkel H, Bauser M, Toschi L, Hess-Stumpp H, Haegebart A, Wick W, Unterberg A, Herold-Mende C, Platten M, von Deimling A. Pan-IDH1 mutant inhibitor BAY 1436032 effectively treats IDH1 mutant astrocytoma in vivo. **Acta Neuropathol** 2017. 133:629-644. doi: 10.1007/s00401-017-1677-y
91. Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, Okonechnikov K, Koelsche C, Reuss D, Capper D, Sturm D, Wirsching HG, Berghoff AS, Baumgarten P, Kratz A, Huang K, Wefers A, Hovestadt V, Sill M, Ellis H, Kurian K, Okuducu AF, Jungk C, Schick M, Bewerunge-Hudler M, Mawrin C, Seiz-Rosenhagen M, Ketter R, Simon M, Lamszus K, Becker A, Koch A, Schittenhelm J, Rushing EJ, Collins VP, Brehmer S, Chavez L, Platten M, Hänggi D, Unterberg A, Paulus W, Wick W, Pfister SM, Mittelbronn M, Preusser M, Herold-Mende C, Weller M, von Deimling A. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. **Lancet Oncol** 2017. 18:682-694. doi: 10.1016/S1470-2045(17)30155-9
90. Dewi DL, Mohapatra SR, Cabanes SB, Adam I, Somarrivas-Patterson LF, Berdel B, Kahloon M, Heilmann K, Heiland I, Schott S, Platten M, Gerhäuser C, Trump S, Opitz CA. Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer. **Oncoimmunol** 2017. 6:e1274477. doi: 10.1080/2162402X.2016.1274477
89. Sahm F, Korshunov A, Schrimpf D, Stichel D, Jones DTW, Capper D, Koelsche C, Reuss D, Kratz A, Huang K, Wefers AK, Schick M, Bewerunge-Hudler M, Mittelbronn M, Platten M, Hänggi D, Jeibmann A, Unterberg A, Herold-Mende C, Pfister SM, Brandner S, Wick W, von Deimling A. Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. **Acta Neuropathol** 2017. 133(2):325-327. doi: 10.1007/s00401-016-1657-7
88. Breckwoldt MO, Gradl J, Wildemann B, Diem R, Hielscher T, Platten M, Wick W, Heiland S, Hähnel S, Bendszus M. Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients. **J Neurol** 2017. 264:341-349. doi: 10.1007/s00415-016-8353-3
87. Lanz TV, Williams SK, Stojic A, Iwantschew S, Grabitz C, Becker S, Boehler LI, Mohapatra SR, Sahm F, Kublbeck G, Nakamura T, Funakoshi H, Wick W, Opitz C, Diem R, Platten M. Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis. **Sci Rep** 2017. 7:41271. doi: 10.1038/srep41271

2016

86. Sonner J, Deumelandt K, Ott M, Thomé C, Rauschenbach K, Mohapatra SR, Adam I, Schulz S, Hofer AC, Feuerer M, Hopf C, Opitz CA, Wick W, Platten M. The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas. **Oncoimmunol** 2016. 5(12):e1240858. doi: 10.1080/2162402X.2016.1240858
85. Kirschbaum K*, Sonner J*, Zeller M, Deumelandt K, Bode J, Sharma R, Krüwel T, Fischer M, Hoffmann A, Costa da Silva M, Muckenthaler MU, Wick W, Tews B, Chen JW, Heiland S, Bendszus M, Platten M, Breckwoldt MO. In vivo nanoparticle imaging of the innate immune cell compartment can serve as a biomarker of disease severity in a mouse model of multiple sclerosis. **Proc Natl Acad Sci USA** 2016. 113:13227-13232. doi: 10.1073/pnas.1609397113
84. Schliesser MG, Claus R, Hielscher T, Grimm C, Weichenhan D, Blaes J, Wiestler B, GGN4, Sahm F, Weiß EK, Weiler M, Baer C, Schmidt-Graf F, Schackert G, Westphal M, Hertenstein A, Roth P, Galldiks N, Hartmann C, Pietsch T, Felsberg J, Reifenberger G, Sabel MC, Winkler F, von Deimling A, Meisner C, Vajkoczy P, Platten M, Weller M, Plass C, Wick W. Prognostic relevance of miRNA-155 methylation in anaplastic glioma. **Oncotarget** 2016. 7(50):82028-82045. doi: 10.18632/oncotarget.13452
83. Lemke D, Pledl HW, Zorn M, Jugold M, Green E, Blaes J, Löw S, Hertenstein A, Ott M, Sahm S, Steffen AC, Weiler M, Winkler F, Platten M, Dong Z, Wick W. Slowing down glioblastoma progression by running or the anti-malarial drug dihydroartemisinin? - Induction of oxidative stress in glioblastoma therapy. **Oncotarget** 2016. 7(35):56713-56725. doi: 10.18632/oncotarget.10723
82. Hertenstein A, Menn O, Wiestler B, Winkler F, Platten M, Wick W, Wick A. Impacts of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. **J Neurooncol** 2016. 129:533-539. doi: 10.1007/s11060-016-2206-x
81. Wick W, Wiestler B, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, Sabel MC, Wick A, Koeppen S, Ketter R, Vajkoczy P, Eyupoglu I, Kaendler S, Kalff R, Hoppold C, Galldiks N, Schmidt-Graf F, Bamberg M, Reifenberger G, Platten M, von Deimling A, Weller M for the Neurooncology Working Group (NOA) of the German Cancer Society. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. **Neuro-Oncol** 2016. 18:1529-1537. doi: 10.1093/neuonc/now133
80. Keil M, Sonner JK, Lanz TV, Oezen I, Bunse T, Bittner S, Meuth SG, Wick W, Platten M. General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation. **J Neuroimmunol** 2016. 297:117-26. doi: 10.1016/j.jneuroim.2016.05.014
79. Laible M, Jariu S, Mackensen F, Schmidt-Bacher A, Platten M, Haas J, Albrecht P, Wildemann B. Adding papillomacular bundle measurements to standard OCT examination does not increase sensitivity to detect prior optic neuritis in MS patients. **PLoS ONE** 2016. 11:e0155322. doi: 10.1371/journal.pone.0155322
78. Kleist C, Mohr E, Gaikwad S, Dittmar L, Kuerten S, Platten M, Mier W, Schmitt M, Opelz G, Terness P. Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis. **J Transl Med** 2016. 14:99. doi: 10.1186/s12967-016-0860-6
77. Wick W, Gorlia T, Bady P, Platten M, van den Bent M, Taphoorn MJB, Steuve J, Brandes AA, Hamou MF, Kosch M, Golfopoulos V, Campone M, Weller M, Roth P, Lhermitte B, Stupp R, Pesce G, Hegi M. Phase II study of radiation therapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). **Clin Cancer Res** 2016. 22(19):4797-4806. doi: 10.1158/1078-0432.CCR-15-3153
76. Diem R, Molnar F, Beisse F, Gross N, Drüschler K, Heinrich S, Joachimsen L, Rauer S, Pielen A, Sühs KM, Linker RA, Huchzermeyer C, Albrecht P, Hassenstein A, Aktas O, Guthoff T, Wilhelm H, Hartmann K, Kümpfel T, Hein K, van Oterendorp C, Grotejohann B, Ihorst G, Maurer J, Müller M, Volkmann M, Wildemann B, Platten M, Wick W, Heesen C, Schiefer U, Wolf S, Lagrèze W. Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial – study protocol. **BMJ Open** 2016. 6:e010956. doi: 10.1136/bmjopen-2015-010956
75. Breckwoldt MO, Bode J, Kurz FT, Hoffmann A, Ochs K, Ott M, Deumelandt K, Krüwel T, Schwarz D, Fischer M, Helluy X, Milford D, Kirschbaum K, Solecki G, Chiblak S, Abdollahi A, Winkler F, Wick W, Platten M, Heiland S, Bendszus M, Tews B. Correlated magnetic resonance imaging and ultramicroscopy (MR-UM) to monitor glioma angiogenesis at single vessel resolution. **ELIFE** 2016. 5:e11712. doi: 10.7554/eLife.11712

74. Sahm F, Schrimpf D, Jones DTW, Meyer J, Kratz A, Reuss D, Capper D, Koelsche C, Korshunov A, Wiestler B, Buchhalter I, Milde T, Selt F, Sturm D, Kool M, Diessl N, Previti C, Bewerunge-Hudler M, Mawrin C, Schüller U, Jungk C, Wick A, Witt O, Platten M, Herold-Mende C, Unterberg A, Pfister S, Wick W, von Deimling A. Next generation sequencing in routine brain tumor diagnostics contributes to an integrated diagnosis and identifies actionable targets. **Acta Neuropathol** 2016. 13:903-10. doi: 10.1007/s00401-015-1519-8
73. Silginer M, Burghardt I, Gramatzki D, Bunse L, Leske H, Rushing EJ, Whitelaw ML, Platten M, Weller M, Roth P. The aryl hydrocarbon receptor links integrin signaling to the TGF- β pathway. **Oncogene** 2016. 35:3260-71. doi: 10.1038/onc.2015.387
72. Ochs K, Ott M, Rauschenbach KJ, Sahm F, Opitz CA, von Deimling A, Wick W, Platten M. Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4. **J Neurochem** 2016. 136:1142-1154. doi: 10.1111/jnc.13503
71. Pilz C, Feyerabend T, Redaelli C, Peter K, Kunze A, Haas K, Esser C, Schäkel K, Wick W, Rodewald HR, Lanz TV, Platten M. Normal mast cell numbers in tissues of AhR-deficient mice. **Exp Dermatol** 2016. 25:62-3. doi: 10.1111/exd.12864

2015

70. Redaelli C, Gaffarogullari E, Brune M, Jäschke A, Becker S, Gröne HJ, Wick W, Platten M, Lanz TV. Toxicity of teriflunomide in aryl hydrocarbon receptor-deficient mice. **Biochem Pharmacol** 2015. 98:484-492. doi: 10.1016/j.bcp.2015.08.111
69. Osswald M, Jung E, Sahm F, Solecki G, Blaes J, Weil S, Venkataramani V, Horstmann H, Wiestler B, Syed M, Huang L, Ratliff M, Jazi KK, Kurz FT, Schmenger T, Lemke D, Gömmel M, Pauli MA, Liao Y, Häring P, Pusch S, Herl V, Steinhäuser C, Krunic D, Jarahian M, Miletic H, Berghoff A, Griesbeck O, Garaschuk O, Preusser M, Weiss S, Liu H, Heiland S, Platten M, Huber PE, Kuner T, von Deimling A, Wick W, Winkler F. Brain tumor cells interconnect to a functional and resistant network. **Nature** 2015. 528:93-98. doi: 10.1038/nature16071
68. Reuss D, Kratz A, Sahm F, Capper D, Schrimpf D, Koelsche C, Hovestadt V, Bewerunge-Hudler M, Jones DTW, Schittenhelm J, Mittelbronn M, Unterberg A, Platten M, Paulus W, Reifenberger G, Tonn JC, Aldape K, Pfister S, Korshunov A, Weller M, Herold-Mende C, Wick W, Brandner S, von Deimling A. Adult IDH wild type astrocytoma biologically and clinically resolve into other tumor entities. **Acta Neuropathol** 2015. 130:407-17. doi: 10.1007/s00401-015-1454-8
67. Reuss D, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A, Sahm F, Koelsche C, Korshunov A, Olar A, Hartmann C, Rijnvald JC, Wesseling P, Unterberg A, Platten M, Wick W, Herold-Mende C, Aldape K, von Deimling A. No difference in age and little in survival between grade IDH mutant diffuse and anaplastic astrocytomas. A grading problem for WHO. **Acta Neuropathol** 2015. 129:867-873. doi: 10.1007/s00401-015-1454-8
66. Puccetti P, Fallarino F, Italiano A, Soubeyran I, MacGrogan G, Debled M, Valasco V, Bodet D, Eimer S, Veldhoen M, Platten M, Bessede A, Guillemin G. Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers. **PLoS ONE** 2015. e122046. doi: 10.1371/journal.pone.0122046
65. Weller M*, Tabatabai G*, Kästner B, Felsberg J, Steinbach J, Wick A, Schnell O, Hau P, Herrlinger U, Sabel M, H Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G*, Wick W*, for the DIRECTOR Study Group. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the randomized phase II DIRECTOR trial. **Clin Cancer Res** 2015. 21:2057-64. doi: 10.1158/1078-0432.CCR-14-2737
64. Kessler T*, Sahm F*, Blaes J, Osswald M, Milford D, Urban S, Ruiz de Almodóvar C, Heiland S, Bendszus M, von Deimling A, Pfenning PN, Winkler F, Platten M, Wick W, Weiler M. Glioma cell-bound VEGFR-2 expression impairs chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. **Oncotarget** 2015. 6:31050-68. doi: 10.18632/oncotarget.2910
63. Bunse L*, Schumacher T*, Sahm F*, Pusch S, Oezen I, Rauschenbach K, Gonzalez M, Solecki G, Osswald M, Capper D, Wiestler B, Winkler F, Herold-Mende C, von Deimling A, Wick W, Platten M. Proximity ligation assay evaluates IDH1R132H presentation in gliomas. **J Clin Invest** 2015. 125:1-14. doi: 10.1172/JCI77780

62. Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Kölsche C, Schweizer L, Korshunov A, Jones DTW, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. **Acta Neuropathol** 2015. 129:133-46. doi: 10.1007/s00401-014-1370-3
61. Ott M, Litzenburger UM, Rauschenbach KJ, Bunse L, Ochs K, Sahm F, Pusch S, Opitz CA, von Deimling A, Wick W, Platten M. Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. **Glia** 2015. 63:78-90. doi: 10.1002/glia.22734

2014

60. Wick W, Fricke H, Junge K, Kobayakov G, Martens T, Heese O, von Deimling A, Pichler J, Harting I, Hartmann C, Debus J, Kunz C, Platten M*, Bendszus M*, Combs SE*. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. **Clin Cancer Res** 2014. 20:6304-6313. doi: 10.1158/1078-0432.CCR-14-0951-T
59. Lemke D, Weiler M, Blaes J, Wiestler B, Jestaedt L, Klein AC, Löw S, Eisele G, Radlwimmer B, Capper D, Mittelbronn M, Schmieder K, Combs SE, Bendszus M, Weller M, Platten M, Wick W. Primary glioblastoma cultures: Can profiling of stem cell markers predict radiotherapy sensitivity? **J Neurochem** 2014. 131:251-64. doi: 10.1111/jnc.12802
58. Wiestler B*, Capper D*, Sill M*, Jones DTW, Hovestadt V, Sturm D, Koelsche C, Bertoni A, Schweizer L, Korshunov A, Weiß EK, Schliesser MG, Radbruch A, Herold-Mende C, Roth P, Unterberg A, Hartmann C, Pietsch T, Reifenberger G, Lichter P, Radlwimmer B, Platten M, Pfister SM, von Deimling A, Weller M, Wick W. Integrated epigenetic and copy-number profiling identifies three clinically and biologically relevant groups of anaplastic gliomas. **Acta Neuropathol** 2014. 128:561-571. doi: 10.1007/s00401-014-1315-x
57. Wiestler B, Capper D, Hovestadt V, Hartmann C, Felsberg J, Platten M, Feiden WE, Keyvani K, Pfister SM, Wiestler OD, Meyermann R, Reifenberger G, Pietsch T, von Deimling A, Weller M, Wick W. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. **Neuro-Oncol** 2014. 16:1630-1638. doi: 10.1093/neuonc/nou138
56. Schumacher T*, Bunse L*, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balss J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller S, Okun J, Stefanovic S, Riemer AB, Sahin U, Friese M, Beckhove P, von Deimling A, Wick W, Platten M. A vaccine targeting mutant IDH1 induces antitumour immunity. **Nature** 2014. 512:324-327. doi: 10.1038/nature13387
55. Bessede A, Gargaro M, Pallotta T, Matino D, Servillo G, Brunacci C, Biciato S, Mazza EMC, Macchiarulo A, Vacca C, Iannitti R, Tissi L, Volpi C, Belladonna ML, Orabona C, Bianchi R, Lanz T, Platten M, Della Fazio MA, Piobbico D, Zelante T, Funakoshi H, Nakamura T, Gilot D, Denison MS, Guillemin GJ, DuHadaway JB, Prendergast GC, Metz R, Geffard M, Boon L, Pirro M, Iorio A, Veyret B, Romani L, Grohmann U, Fallarino F, Puccetti P, Aryl hydrocarbon receptor control of a disease tolerance defense pathway. **Nature** 2014. 511:184-192. doi: 10.1038/nature13323
54. Litzenburger UM*, Opitz CA*, Sahm F, Rauschenbach K, Trump S, Winter M, Ott M, Ochs K, Lutz C, Liu X, Anastasov N, Lehmann I, Höfer T, von Deimling A, Wick W, Platten M. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. **Oncotarget** 2014. 5:1038-1051. doi: 10.18632/oncotarget
53. Wiestler B, Radbruch A, Osswald M, Combs SE, Jungk C, Winkler F, Bendszus M, Unterberg A, Platten M, Wick W, Wick A. Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. **J Neurooncol** 2014. 117:85-92. doi: 10.1007/s11060-013-1356-3
52. Blaes J, Weiler M, Sahm F, Hentschel B, Osswald M, Czabanka M, Thomé CM, Schliesser MG, Pusch S, Luger S, Winkler F, Radbruch A, Jugold M, Simon M, Steinbach JP, Schackert G, Tatagiba M, Westphal M, Tonn JC, Gramatzki D, Pietsch T, Hartmann C, Glimm H, Vajkoczy P, von Deimling A, Platten M, Weller M, Wick W. NDRG1 prognosticates the natural course of disease in WHO grade II glioma. **J Neurooncol** 2014. 117:25-32. doi: 10.1007/s11060-013-1357-2
51. Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Hodecker SC, Osswald M, Meisner C, Hielscher T, Rübmann P, Pfenning PN, Ronellenfitsch M, Kempf T, Schölzer M, Abdollahi A, Lang F, Bendszus M, von Deimling A, Winkler F, Weller M, Vajkoczy P, Platten M, Wick W. NDRG1 confers resistance to alkylating chemotherapy by stabilizing MGMT. **Proc Natl Acad Sci USA** 2014. 111:409-414. doi: 10.1073/pnas.1314469111

2013

50. Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones D, Wiestler B, Böhmer K, Meyer J, Mawrin C, Hartmann C, Mittelbronn M, Platten M, Paulus W, Seiz-Rosenhagen M, Herold-Mende C, Unterberg A, Schittenhelm J, Weller M, Pfister S, Wick W, Korshunov A, von Deimling A. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. **Acta Neuropathol** 2013. 126:907-915. doi: 10.1007/s00401-013-1195-5
49. Ochs K, Sahm F, Opitz CA, Oezen I, Couraud PO, von Deimling A, Wick W, Platten M. Immature mesenchymal stem cell-like pericytes mediate immunosuppression in human malignant glioma. **J Neuroimmunol** 2013. 265:106-116. doi: 10.1016/j.jneuroim.2013.09.011
48. Wick W, Meisner C, Hentschel B, Platten M, Wiestler B, Schilling A, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Löffler M, Simon M, Reifenberger G, Weller M, for the Neurooncology Working Group (NOA) of the German Cancer Society and the German Glioma Network (GGN). Prognostic or predictive value of MGMT promoter methylation depends on IDH1 mutation status: an analysis from the NOA-04 trial and the German Glioma Network. **Neurology** 2013. 81:1515-1522. doi: 10.1212/WNL.0b013e3182a95680
47. Lanz TV, Becker S, Osswald M, Bittner S, Schuhmann MK, Opitz CA, Gaikwad S, Wiestler B, Litzenburger UM, Sahm F, Ott M, Iwantschew S, Grabitz C, Mittelbronn M, von Deimling A, Winkler F, Meuth SG, Wick W, Platten M. Endothelial protein kinase C β as a therapeutic target stabilizing blood brain barrier disruption in experimental autoimmune encephalomyelitis. **Proc Natl Acad Sci USA** 2013. 110:14735-14740. doi: 10.1073/pnas.1302569110
46. Wick W, Steinbach JP, Platten M, Hartmann C, Wenz F, von Deimling A, Shei P, Moreau-Donnet V, Stoffregen C, Combs SE. Enzastaurin before and concomitant with radiation therapy, followed by Enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. **Neuro-Oncol** 2013. 15:1402-1412. doi: 10.1093/neuonc/not100
45. Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. **Acta Neuropathol** 2013. 126:443-451. doi: 10.1007/s00401-013-1156-z
44. Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, Platten M, Dittmann LM, Meisner C, Felsberg J, Hoppold C, Simon M, Nikkha G, Papsdorf K, Steinbach JP, Sabel M, Grimm C, Weichenhan D, Tews B, Reifenberger G, Capper D, Müller W, Plass C, Weller M and Wick W for the Neurooncology Working Group (NOA) of the German Cancer Society. Malignant astrocytomas of elderly patients have a distinct molecular profile: An analysis of the NOA-08 study collective. **Neuro-Oncol** 2013. 15:1017-1026. doi: 10.1093/neuonc/not043
43. Sahm F, Oezen I, Opitz CA, Radlwimmer B, von Deimling A, Ahrendt T, Adams S, Bode, HB, Guillemin G, Wick W, Platten M. The endogenous tryptophan metabolite and NAD⁺ precursor quinolinic acid confers resistance of gliomas to oxidative stress. **Cancer Res** 2013. 73:1-10. doi: 10.1158/0008-5472.CAN-12-3831
42. Reuss DE, Mucha J, Holtkamp N, Müller U, Berlien HP, Mautner VF, Ehemann V, Platten M, Scheffzek K, von Deimling A. Functional MHC class II is upregulated in neurofibromin-deficient Schwann cells. **J Invest Dermatol** 2013. 133:1372-1375. doi: 10.1038/jid.2012.488
41. Weiler M, Pfenning PN, Thiebold AL, Blaes J, Jaestedt L, Gronych J, Dittmann LM, Berger B, Jugold M, Kosch M, Combs, SE, von Deimling A, Weller M, Bendszus M, Platten M, Wick W. Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment. **Oncogene** 2013. 32:1099-1109. doi: 10.1038/onc.2012.137

2012

40. Ott M, Litzenburger UM, Sahm F, Rauschenbach KJ, Tudoran R, Hartmann C, Marquez VE, von Deimling A, Wick W, Platten M. Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase. **PLoS ONE** 2012. 7:e47663. doi: 10.1371/journal.pone.0047663
39. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkha G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper M, Melms A, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, for the Neurooncology Working Group (NOA) of the German Cancer Society. The NOA-08 randomized phase III trial of chemotherapy versus radiotherapy for malignant astrocytoma in the elderly. **Lancet Oncol** 2012. 13:707-715. doi: 10.1016/S1470-2045(12)70164-X

38. Lemke D, Pfenning PN, Sahm F, Klein AC, Kempf T, Warnken U, Schnölzer M, Tudoran R, Weller M, Platten M, Wick W. Costimulatory protein 4lgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. **Clin Cancer Res** 2012. 18:105-117. doi: 10.1158/1078-0432.CCR-11-0880

2011

37. Opitz CA*, Litzenburger UM*, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M. An endogenous ligand of the human aryl hydrocarbon receptor promotes tumor formation. **Nature** 2011. 478:197-203. doi: 10.1038/nature10491
36. Mittelbronn M, Platten M, Zeiner P, Dombrowski Y, Frank B, Zachskorn C, Harter PN, Weller M, Wischhusen J. Macrophage migration inhibitory factor (MIF) expression in human malignant glioma contributes to immune suppression and tumor progression. **Acta Neuropathol** 2011. 122:353-365. doi: 10.1007/s00401-011-0858-3
35. Hertenstein A, Schumacher T, Litzenburger U, Opitz CA, Falk CS, Serafini T, Wick W, Platten M. Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10. **Biochem Pharmacol** 2011. 82:632-641. doi: 10.1016/j.bcp.2011.06.013
34. Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, Lutz C, Wick W, Platten M. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. **PLoS ONE** 2011. 6:e19823. doi: 10.1371/journal.pone.0019823
33. Seidel C, Dörner N, Osswald M, Wick A, Platten M, Bendszus M, Wick W. Does age matter? – An MRI study on peritumoral edema in newly diagnosed primary glioblastoma. **BMC Cancer** 2011. 11:127. doi: 10.1186/1471-2407-11-127
32. Wick A, Dörner N, Schäfer N, Hofer S, Heiland S, Schemmer D, Platten M, Weller M, Bendszus M, Wick W. Bevacizumab does not increase the risk of remote relapse in malignant glioma. **Ann Neurol** 2011. 69:586-592. doi: 10.1002/ana.22336

2010

31. Lanz TV*, Ding Z*, Ho PP*, Luo J, Agrawal AN, Srinagesh H, Axtell R, Zhang H, Platten M, Wyss-Coray T, Steinman L. Angiotensin II sustains brain inflammation in mice via TGF-beta. **J Clin Invest** 2010. 120:2782-94. doi: 10.1172/JCI41709
30. Berger B, Capper D, Lemke D, Pfenning PN, Platten M, Weller M, von Deimling A, Wick W, Weiler M. Defective p53 antiangiogenic signaling in glioblastoma. **Neuro-Oncol** 2010. 12:894-907. doi: 10.1093/neuonc/noq051
29. Lanz T, Opitz C, Ho P, Agrawal A, Lutz C, Weller M, Mellor A, Steinman L, Wick W, Platten M. Mouse mesenchymal stem cells suppress antigen-specific TH-cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). **Stem Cells Dev** 2010. 19:657-668. doi: 10.1089/scd.2009.0385
28. Wick A, Schäfer N, Dörner N, Schemmer D, Platten M, Bendszus M, Wick W. Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome. **J Neurooncol** 2010. 97(1):157-8. doi: 10.1007/s11060-009-0003-5

2009

27. Platten M*, Youssef S*, Hur EM, Ho PP, Han MH, Lanz TV, Phillips LK, Goldstein MJ, Bhat R, Raine CS, Sobel RA, Steinman L. Blocking angiotensin converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. **Proc Natl Acad Sci USA** 2009. 106:14948-14953. doi: 10.1073/pnas.0903958106
26. Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Köppel A, Tolosa E, Hoberg M, Anderl J, Aicher WK, Weller M, Wick W, Platten M. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon- β and protein kinase R. **Stem Cells** 2009. 27:909-919. doi: 10.1002/stem.7

2008

25. Wick W, Stupp R, Beule AC, Bromberg J, Wick A, Ernemann U, Platten M, Marosi C, Mason WP, van den Bent M, Weller M, Rorden C, Karnath HO. A novel tool to analyse MRI recurrence patterns in glioblastoma. **Neuro Oncol** 2008. 10:1019-1024. doi: 10.1215/15228517-2008-058

2007

24. Kaper T, Looger LL, Takanaga H, Platten M, Steinman L, Frommer WB. Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. **PLoS Biology** 2007. 5:e257. doi: 10.1371/journal.pbio.0050257
23. Platten M, Opitz CA, Kohlhof P, Hegenbart U, Ho AD, Wick W. Painful neuropathy due to intraneural leukemic spread in a patient with acute myeloid leukemia. **Neurology** 2007. 69:707. doi: 10.1212/01.wnl.0000275547.39894.a6
22. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W. Efficacy and tolerability of temozolomide in an one week on / one week off regimen in patients with recurrent glioma. **J Clin Oncol** 2007. 25:3357. doi: 10.1200/JCO.2007.10.7722

2005

21. Ho PP, Fontoura P, Platten M, Sobel RA, DeVoss JJ, Lee LY, Kidd BA, Tomooka B, Capers J, Agrawal A, Gupta R, Zernik Y, Yee MK, Lee BJ, Garren H, Robinson WH, Steinman L. A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune disease. **J Immunol** 2005. 175:6226-6234. doi: 10.4049/jimmunol.175.9.6226
20. Platten M*, Ho PP*, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, Sobel RA, Selley ML, Steinman L. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. **Science** 2005. 310:850-855. doi: 10.1126/science.1117634

2004

19. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. **Cancer Res** 2004. 64:7954-7961. doi: 10.1158/0008-5472.CAN-04-1013

2003

18. Friese MA, Platten M, Lutz SZ, Naumann U, Aulwurm S, Bischof F, Bühring HJ, Dichgans J, Rammensee HG, Steinle A, Weller M. MICA/ NKG2D-mediated immunogene therapy of experimental gliomas. **Cancer Res** 2003. 63:8996-9006. PMID:14695218.
17. Platten M, Eitel K, Wischhusen J, Dichgans J, Weller M. Involvement of protein kinase Cdelta and extracellular signal-regulated kinase-2 in the suppression of microglial inducible nitric oxide synthase expression by N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast). **Biochem Pharmacol** 2003. 66:1263-1270. doi: 10.1016/s0006-2952(03)00449-0
16. Platten M, Kretz A, Naumann U, Aulwurm S, Egashira K, Isenmann S, Weller M. Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. **Ann Neurol** 2003. 54:388-392. doi: 10.1002/ana.10679

2002

15. Ernemann U, Skalej M, Hermisson M, Platten M, Jaffe R, Voigt K. Primary cerebral non-Langerhans cell histiocytosis: MRI and differential diagnosis. **Neuroradiology** 2002. 44:759-763. doi: 10.1007/s00234-002-0819-6
14. Herrlinger U, Küker W, Platten M, Dichgans J, Weller M. First-line therapy with temozolomide induces regression of primary CNS lymphoma. **Neurology** 2002. 58:1573-1574. doi: 10.1212/wnl.58.10.1573

2001

13. Platten M, Wick W, Wischhusen J, Weller M. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon-gamma (IFN-gamma). **Br J Pharmacol** 2001. 134:1279-1284. doi: 10.1038/sj.bjp.0704373
12. Leitlein J, Aulwurm S, Waltereit R, Naumann U, Wagenknecht B, Garten W, Weller M, Platten M. Processing of immunosuppressive pro-TGF- β 1,2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. **J Immunol** 2001. 166:7238-7243. doi: 10.4049/jimmunol.166.12.7238
11. Wick W, Platten M, Weller W. Glioma cell invasion: regulation of metalloproteinase activity by TGF- β . **J Neurooncol** 2001. 53:177-185. doi: 10.1023/a:1012209518843

10. Wick W, Grimm C, Wild-Bode C, Platten M, Arpin M, Weller M. Ezrin-dependent promotion of glioma cell clonogenicity, motility and invasion mediated by Bcl-2 and transforming growth factor- β 2. **J Neurosci** 2001. 21:3360-3368. doi: 10.1523/JNEUROSCI.21-10-03360.2001
9. Platten M, Wild-Bode C, Wick W, Leitlein J, Dichgans J, Weller M. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits TGF- β release and reduces migration and invasiveness of human malignant glioma cells. **Int J Cancer** 2001. 93:53-61. doi: 10.1002/ijc.1289
8. Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bähr M, Ohgaki H, Ashkenazi A, Weller M. The soluble decoy receptor-3 is expressed by malignant glioma and suppresses CD95 ligand-induced apoptosis and chemotaxis. **Cancer Res** 2001. 61:2759-2765. PMID:11289159.

2000

7. Roth W, Wild-Bode C, Platten M, Grimm C, Melkonyan HS, Dichgans J, Weller M. Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. **Oncogene** 2000. 19:4210-20. doi: 10.1038/sj.onc.120378
6. von Deimling A, Fimmers R, Schmidt MC, Bender B, Fassbender F, Nagel J, Jahnke R, Kaskel P, Duerr EM, Koopmann J, Maintz D, Steinbeck S, Wick W, Platten M, Müller DJ, Przkora R, Waha A, Blumcke B, Wellenreuther R, Meyer-Puttlitz B, Schmidt O, Mollenhauer J, Poustka A, Stangl AP, Lenartz D, von Ammon K. Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. **J Neuropathol Exp Neurol** 2000. 59:544-58. doi: 10.1093/jnen/59.6.544
5. Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J, Weller M. Transforming growth factors β 1 (TGF- β 1) and TGF- β 2 promote glioma cell migration via up-regulation of α V β 3 integrin expression. **Biochem Biophys Res Commun** 2000. 268:607-11. doi: 10.1006/bbrc.2000.2176

1998

4. Batchelor TT, Platten M, Hochberg FH. Immunoadsorption therapy for paraneoplastic syndromes. **J Neurooncol** 1998. 40:131-6. doi: 10.1023/a:1006136219490
3. Batchelor TT, Platten M, Palmer-Toy DE, Hunter GJ, Lev MH, Dalmau J, Hochberg FH. Chorea as a paraneoplastic complication of Hodgkin's disease. **J Neurooncol** 1998. 36:185-90. doi: 10.1023/a:1005860103173

1997

2. Platten M, Meyer-Puttlitz B, Blumcke I, Waha A, Wolf HK, Nothen MM, Louis DN, Sampson JR, von Deimling A. A novel splice site associated polymorphism in the tuberous sclerosis 2 (TSC2) gene may predispose to the development of sporadic gangliogliomas. **J Neuropathol Exp Neurol** 1997. 56:806-10. PMID:9210877.

1996

1. Platten M, Giordano MJ, Dirven CM, Gutmann DH, Louis DN. Up-regulation of specific NF 1 gene transcripts in sporadic pilocytic astrocytomas. **Am J Pathol** 1996. 149:621-7. PMID:PMC1865298.

REVIEW ARTICLES / COMMENTARIES

2026

89. Eris C, Zu C, Xiao Y, Platten M, Sun C. Regulation of immune checkpoint molecules in cancer immune evasion and therapy. **Nat Rev Cancer** 2026. 26(8):560-585. doi: 10.1038/s41568-026-00934-y
88. Stojanovic A, Giorgetta S, Vonhören D, Kriehoff-Henning EI, Platten M, Loges S, Tugues S, Cerwenka A. Tissue-specific spatial regulation of innate immune checkpoints in cancer. **Cancer Discov** 2026. 16(5):857-875. doi: 10.1158/2159-8290.CD-25-2112
87. Moreno-Sanchez PM*, Rezaei-pour M*, Inderberg EM, Platten M, Golebiewska A. Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity. **Nat Cancer** 2026. 7(1):29-42. doi: 10.1038/s43018-025-01097-9

86. Winkler F, Heuer S, Althammer F, Augustin H, Beleggia F, Demir IE, Koenig J, Kuner R, Kuner T, Loges S, Platten M, Reinhardt HC, Rich JM, Sahm F, Stassart RM, Thiel V, Trumpp A, Venkataramani V, Wick W, Karreman MA. Cancer neuroscience: The past, the present, and the road ahead. **Cell** 2026. 189(8):2464-2489. doi: 10.1016/j.cell.2026.03.018

2025

85. Bunse L, Bunse T, Kilian M, Quintana F, Platten M. The immunology of brain tumors. **Sci Immunol** 2025. 10:eads0449. doi: 10.1126/sciimmunol.ads0449
84. Wen PY*, Weller M*, Lee EQ,1 Touat M, Khasraw M,4 Rahman R, Platten M, Lim M, Winkler F, Horbinski C, Verhaak RGW, Huang RY, Ahluwalia MS, Albert NL, Tonn JC, Schiff D, Barnholtz-Sloan JS, Ostrom Q, Aldape KD, Batchelor TT, Bindra RS, Chiocca EA, Cloughesy TF, DeGroot JF, French P,24 Galanis E, Galldiks N, Gilbert MR, Hegi ME, Lassman AB, Le Rhun E, Mehta MP, Mellinghoff IK, Minniti G, Roth P, Sanson M, Taphoorn MJB, von Deimling A, Weiss T, Wick W, Zadeh G, Reardon DA, Chang SM*, Short SC*, van den Bent MJ*, Preusser M*. Glioblastoma in Adults: Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. **Neuro-Oncol** 2025. 27(11):2751-2788. doi: 10.1093/neuonc/noaf177
83. Platten M. IDH mutation and microenvironment in gliomas: do immunotherapy approaches matter? **Curr Opin Neurol** 2025. 38(6):706-710. doi: 10.1097/WCO.0000000000001426
82. Tabatabai G*, Platten M*, Preusser M*, Weller M*, Wick W*, van den Bent M*. Treatment of glioblastoma patients with personalized vaccines outside clinical trials: Lessons ignored? **Neuro-Oncol** 2025. 27:302-305. doi: 10.1093/neuonc/noae225

2024

81. Platten M, Bunse L. Heating-up IDH-mutant gliomas. **New Engl J Med** 2024. 391:2170-2172. doi: 10.1056/NEJMcibr2410562
80. Werner JM, Petrescu GED, Boele F, Preusser M, Platten M, Chalmers AJ, Short SC, Piil K. Chairing scientific sessions at international neuro-oncology meetings: An EANO guide for early-career professionals. **Neuro-Oncol Pract** 2024. 11:673-676. doi: 10.1093/nop/npae060
79. Hotchkiss KM, Karschnia P, Schreck KC, Guerts M, Cloughesy TF, Hsue J, Duke ES, Lathia J, Ashley DM, Nduom EK, Long G, Singh K, Chalmers A, Ahluwalia MS, Heimberger A, Bagley S, Todo T, Verhaak R, Kelly PD, Harvey-Jumper S, de Groot J, Patel A, Fecci P, Parney I, Wykes V, Watts C, Burns T, Sanai N, Preusser M, Tonn JC, Drummond KJ, Platten M, Das S, Tanner K, Vogelbaum MA, Weller M, Whittle JR, Berger MS, Khasraw M. A Brave New Paradigm for Glioma Drug Development. **Lancet Oncol** 2024. 25:e512-e519. doi: 10.1016/S1470-2045(24)00190-6
78. Göpfrich K, Platten M, Frischknecht F, Fackler OT. Bottom-up synthetic biology. **Nature Nanotechnol** 2024. 19:1587-1596. doi: 10.1038/s41565-024-01744-9
77. Taphoorn MJB, Galldiks N, Preusser M, Platten M, Short S. European Association of Neuro-Oncology's 30th anniversary: A successful and growing relationship with Neuro-Oncology Practice. **Neuro-Oncol Pract** 2024. 11:509-510. doi: 10.1093/nop/npae061
76. Preusser M, Platten M, Short S. Celebrating the 30th Anniversary of the European Association of Neuro-Oncology. **Neuro-Oncol** 2024. 26(10):1739-1741. doi: 10.1093/neuonc/noae039

2023

75. Zhao B, Kilian M, Bunse T, Platten M, Bunse L. Tumor-reactive T helper cells in the context of vaccination against glioma. **Cancer Cell** 2023. 41:1829-1834. doi: 10.1016/j.ccell.2023.09.013
74. Bayas A, Berthele A, Blank N, Dreger P, Faissner S, Friesse MA, Gerdes LA, Grauer OM, Häussler V, Heesen C, Janson D, Korporal-Kuhnke M, Kowarik M, Kröger N, Lünemann JD, Martin R, Meier U, Meuth S, Muraro P, Platten M, Schirmer L, Stürner KH, Stellmann JP, Scheid C, Bergh FT, Warnke C, Wildemann B, Ziemssen T. Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline. **Ther Adv Neurol Disord** 2023. 16:17562864231180730. doi: 10.1177/17562864231180730

73. Singh K, Hotchkiss KM, Parney IF, De Groot J, Sahebjam S, Sanai N, Platten M, Galanis E, Lim M, Wen PY, Minniti G, Colman H, Cloughesy TF, Mehta MP, Geurts M, Arrillaga-Romany I, Desjardins A, Tanner K, Short S, Arons D, Duke E, Wick W, Bagley SJ, Ashley DM, Kumthekar P, Verhaak R, Chalmers AJ, Patel AP, Watts C, Fecci PE, Batchelor TT, Weller M, Vogelbaum MA, Preusser M, Berger MS, Khasraw M. Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. **Nat Med** 2023. 29:2402-2405. doi: 10.1038/s41591-023-02464-8
72. Winkler F, Venkatesh HS, Amit M, Batchelor T, Demir IE, Deneen B, Gutmann DH, Hervey-Jumper S, Kuner T, Mabbott D, Platten M, Rolls A, Sloan E, Wang TC, Wick W, Venkataramani V, Monje M. Cancer neuroscience: state of the field, emerging directions. **Cell** 2023. 186:1689-1707. doi: 10.1016/j.cell.2023.02.002
71. Platten M, Grassl N. Vaccines in Glioma – Antigens Matter. **J Clin Oncol** 2023. 41:1466-1469. doi: 10.1200/JCO.22.00996
70. Miller JL*, Gonzalez Castro LN*, McBrayer S, Weller M, Cloughesy T, Portnow J, Andronesi O, Barnholtz-Sloan JS, Baumert BG, Berger MS, Bi WL, Bindra R, Cahill D, Chang SM, Costello JF, Horbinski C, Huang RY, Jenkins RB, Ligon KL, Mellinghoff IK, Nabors LB, Platten M, Reardon DA, Shi DD, Schiff D, Wick W, Yan HJ, von Deimling A, van den Bent M, Kaelin WG, Wen PY. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. **Neuro-Oncol** 2023. 25:4-25. doi: 10.1093/neuonc/noac207

2022

69. Bunse L, Bunse T, Krämer C, Chih YC, Platten M. Clinical and Translational Advances in Glioma Immunotherapy. **Neurotherapeutics** 2022. 19:1799-1817. doi: 10.1007/s13311-022-01313-9
68. Elmadany N, Alhalabi OT, Platten M, Bunse L. Site-Specific Considerations on Engineered T Cells for Malignant Gliomas. **Biomedicines** 2022. 10:1738. doi: 10.3390/biomedicines10071738
67. Bunse L, Platten M. How mutant isocitrate dehydrogenase orchestrates immune cells. **Neuro-Oncol** 2022. 24:210-2. doi: 10.1093/neuonc/noab266
66. Hwang EI, Sayour EJ, Flores CT, Grant G, Wechsler-Reya R, Hoang-Minh LB, Kieran MW, Salcido J, Prins RM, Figg JW, Platten M, Candelario KM, Hale PG, Blatt JE, Governale LS, Okada H, Mitchell DA, Pollack IF. The current landscape of immunotherapy for pediatric brain tumors. **Nat Cancer** 2022. 3:11-24. doi: 10.1038/s43018-021-00319-0

2021

65. Kilian M, Bunse T, Wick W, Platten M, Bunse L. Genetically Modified Cellular Therapies for Malignant Gliomas. **Int J Mol Sci** 2021. 22:12810. doi: 10.3390/ijms222312810
64. Platten M, Bunse L, Wick W. Hirntumorimmuntherapie – Möglichkeiten und Herausforderungen der Personalisierung. **Nervenarzt** 2021. 92:996-1001. doi: 10.1007/s00115-021-01178-x
63. Singh K, Batich K, Wen PY, Tan AC, Bagley SJ, Lim M, Platten M, Colman H, Ashley DM, Chang SM, Rahman R, Galanis E, Mansouri A, Puduvalli VK, Reardon DA, Sahebjam S, Sampson JH, Simes J, Berry D, Zadeh G, Cloughesy TF, Mehta MP, Piantadosi S, Weller M, Heimberger AB, Khasraw M. Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. **Clin Cancer Res** 2021. 28:585-593. doi: 10.1158/1078-0432.CCR-21-2681
62. Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Stangel M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghighi A, Hartung HP, Heidenreich F, Hoffmann O, Hunter ZR, Kallmann B, Kleinschnitz C, Klotz L, Leussink V, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber MS, Weber F, Zettl UK, Ziemssen T, Zipp F; Multiple Sclerosis Therapy Consensus Group' (MSTCG). Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). **Ther Adv Neurol Disord** 2021. 14:17562864211039648. doi: 10.1177/17562864211039648

61. Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Stangel M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghighi A, Hartung HP, Heidenreich F, Hoffmann O, Hunter ZR, Kallmann B, Kleinschnitz C, Klotz L, Leussink V, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber MS, Weber F, Zettl UK, Ziemssen T, Zipp F; die Multiple Sklerose Therapie Konsensus Gruppe (MSTKG). [Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis (white paper)]. **Nervenarzt** 2021. 92(8):773-801. doi: 10.1007/s00115-021-01157-2
60. Platten M, Bunse L, Wick W. Emerging targets for anticancer vaccination: IDH. **ESMO Open** 2021. 6:100214. doi: 10.1016/j.esmoop.2021.100214
59. Tan AC, Bagley SJ, Wen PY, Lim M, Platten M, Colman H, Ashley DM, Wick W, Chang SM, Galanis E, Mansouri A, Khagi S, Mehta MP, Heimberger AB, Puduvalli VK, Reardon DA, Sahebjam S, Simes RJ, Antonia SJ, Berry D, Kharshaw M. A systematic review of combinations of targeted or immunotherapy in advanced solid tumors. **J Immunother Cancer** 2021. 9:e002459. doi: 10.1136/jitc-2021-002459
58. Platten M, Friedrich M, Panitz V, Wainwright DA, Opitz C. Tryptophan metabolism in brain tumors - IDO and beyond. **Curr Opin Immunol** 2021. 70:57-66. doi: 10.1016/j.coi.2021.03.005
57. Chuntova P*, Chow F*, Watchmaker P*, Galvez M, Heimberger AB, Newell E, Diaz A, DePinho RA, Li M, Wherry EJ, Mitchell D, Terabe M, Wainwright D, Bersofsky JA, Herold-Mende C, Heath JR, Lim M, Margolin KA, Chiocca EA, Kasahara N, Ellingson BM, Brown C, Chen Y, Fecci P, Reardon DA, Dunn G, Liao LM, Costello JF, Wick W, Cloughesy T, Timmer WC, Wen PY, Prins R*, Platten M*, Okada H*. Glioblastoma: Unique challenges for glioblastoma immunotherapy? - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. **Neuro-Oncol** 2021. 23:356-375. doi: 10.1093/neuonc/noaa277
56. Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Rudà R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W, for the European Association for Neuro-Oncology (EANO) Task Force on Diffuse Gliomas. EANO guideline on the diagnosis and treatment of diffuse gliomas of adulthood. **Nat Rev Clin Oncol** 2021. 18(3):170-186. correction 2021. 19():357-358. doi: 10.1038/s41571-022-00623-3

2020

55. Wen PY, Weller M, Lee EQ, Alexander BA, Barnholtz-Sloan JS, Barthel F, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi M, Horbinsky C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellinger IK, Minniti G, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC, Tonn JC, Tsang J, Verhaak R, von Deimling A, Wick W, Zadeh G, Reardon DA, Aldape K, van den Bent M. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. **Neuro-Oncol** 2020. 22:1073-1113. doi: 10.1093/neuonc/noaa106
54. Opitz CA, Somarrivas Patterson LF, Dewi DL, Mohapatra SR, Sadik A, Platten M, Trump S. Tryptophan metabolism and therapeutic potential in cancer. **Br J Cancer** 2020. 122:30-44. doi: 10.1038/s41416-019-0664-6
53. Platten M. Driving mesenchymal transition in glioblastoma. **Neuro-Oncol** 2020. 22:1-2. doi: 10.1093/neuonc/noz195

2019

52. Lanz TV, Pröbstel AK, Mildenerberger I, Platten M, Schirmer L. Single-cell high-throughput technologies in cerebrospinal fluid research and diagnostics. **Front Immunol** 2019. 10:1302. doi: 10.3389/fimmu.2019.01302
51. Mildenerberger I, Hofheinz RD, Platten M. Treatment-associated neurological symptoms of cancer patients and their treatment. **Nervenarzt** 2019. 90:587-593. doi: 10.1007/s00115-019-0712-8
50. Platten M. How to integrate immunotherapy into standard of care in glioblastoma. **Neuro-Oncol** 2019. 21:699-700. doi: 10.1093/neuonc/noz043
49. Platten M, Fallarino F, Nollen E, Opitz C. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. **Nat Rev Drug Discov** 2019. 18:379-401. doi: 10.1038/s41573-019-0016-5
48. Schiff D, van den Bent M, Vogelbaum M, Wick W, Miller CR, Taphoorn M, Pope W, Brown P, Platten M, Jalali R, Armstrong T, Wen P. Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. **Neuro-Oncol** 2019. 21:837-853. doi: 10.1093/neuonc/noz033

47. Platten M. Practice-changing developments in neuro-oncology - embracing heterogeneity. **Ther Adv Neurol Disord** 2019. 12:1756286419827688. doi: 10.1177/1756286419827688

2018

46. Friedrich M, Bunse L, Wick W, Platten M. Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas. **Curr Opin Oncol** 2018. 30:368-374. doi: 10.1097/CCO.0000000000000478
45. Wick W, Platten M. Understanding and treating glioblastoma. **Neurol Clin** 2018. 36:485-499. doi: 10.1016/j.ncl.2018.04.006
44. Platten M, Bunse L, Riehl D, Bunse T, Ochs K, Wick W. Vaccines strategies in gliomas. **Curr Treat Options Neurol** 2018. 20:11. doi: 10.1007/s11940-018-0498-1
43. Platten M, Reardon DA. Concepts for Immunotherapies in Gliomas. **Semin Neurol** 2018. 38:62-72. doi: 10.1055/s-0037-1620274
42. Wick A, Kessler T, Elia AEH, Winkler F, Batchelor TT, Platten M, Wick W. Glioblastoma in the elderly: solid conclusions build on shifting sand? **Neuro-Oncol** 2018. 20(2):174-183. doi: 10.1093/neuonc/nox133
41. Ochs K, Deumelandt K, Platten M. Synergy of vaccination and agonist OX40 treatment – towards mechanism-driven combination of glioma immunotherapy. **Neuro-Oncol** 2018. 20(1):4-5. doi: 10.1093/neuonc/nox169

2017

40. Platten M. EGFRvIII vaccine in glioblastoma - InACT-IVe or not ReACTive enough? **Neuro-Oncol** 2017. 19:1425-26. doi: 10.1093/neuonc/nox16
39. Mildenberger I, Bunse L, Ochs K, Platten M. The promises of Immunotherapy in Gliomas. **Curr Opin Neurol** 2017. 30(6):650-658. doi: 10.1097/WCO.0000000000000491
38. Ochs K, Bunse L, Mildenberger I, Wick W, Platten M. Immuntherapie bei Gliomen. **Onkologe** 2017. 23:831-837. doi: 10.1007/s00761-017-0258-y
37. Weller M, Roth P, Preusser M, Wick W, Reardon DA, Platten M, Sampson JH. Vaccine-based Immunotherapeutic Approaches to Gliomas and beyond. **Nat Rev Neurol** 2017. 13:363-374. doi: 10.1038/nrneurol.2017.6
36. Fatar M, Akin I, Borggrefe M, Platten M, Alonso A. Interaction between heart and brain in sudden cardiac death. **Herz** 2017. 42:171-175. doi: 10.1007/s00059-017-4547-4

2016

35. Wick W, Hertenstein A, Platten M. Neurological sequelae of cancer immunotherapies and targeted therapies. **Lancet Oncol** 2016. 17:e529-e541. doi: 10.1016/S1470-2045(16)30571-X
34. Hertenstein A, Platten M, Wick W. Highlights in Central Nervous System Tumors. **JAMA Oncol** 2016. 2:1535-1536. doi: 10.1001/jamaoncol.2016.3673
33. Platten M, Bunse L, Wick W, Bunse T. Concepts in glioma immunotherapy. **Cancer Immunol Immunother** 2016. 65:1269-75. doi: 10.1007/s00262-016-1874-x
32. Wick W, Platten M, Wick A, Hertenstein A, Radbruch A, Bendszus M, Winkler F. Current Status and Future Directions of anti-angiogenic Therapy for Gliomas. **Neuro-Oncol** 2016. 18:315-28. doi: 10.1093/neuonc/nov180

2015

31. Platten M, Offringa R. Cancer immunotherapy: exploiting neoepitopes. **Cell Reserach** 2015. 25:887-8. doi: 10.1038/cr.2015.66
30. Herrlinger U, Platten M. [Treatment of the glioma microenvironment]. **Nervenarzt** 2015. 86:684-91. doi: 10.1007/s00115-014-4225-1
29. Platten M, Wick W. Tregs in glioma – the jury is still out. **Neuro-Oncol** 2015. 17:769-70. doi: 10.1093/neuonc/nov034
28. Platten M, von Knebel Doeberitz N, Oezen I, Wick W, Ochs K. Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. **Front Immunol** 2015. 5:673. doi: 10.3389/fimmu.2014.00673
27. Wick W, Wiestler B, Platten M. Treatment of anaplastic glioma. **Cancer Res Treat** 2015. 163:89-101. doi: 10.1007/978-3-319-12048-5_6

26. Schumacher T, Bunse L, Wick W, Platten M. Mutant IDH1: an immunotherapeutic target in tumors. **Oncoimmunol** 2015. 3:e974392. doi: 10.4161/2162402X.2014.974392

2014

25. Vacchelli E, Aranda F, Eggermont A, Sautes-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: IDO inhibitors in cancer therapy. **Oncoimmunol** 2014. 3:e957994. doi: 10.4161/21624011.2014.957994
24. Wick W, Platten M. Understanding and targeting alkylator resistance in glioblastoma. **Cancer Discovery** 2014. 4:1020-1022. doi: 10.1158/2159-8290.CD-14-0918
23. Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M, Reifenberger G. MGMT testing--the challenges for biomarker-based glioma treatment. **Nat Rev Neurol** 2014. 10:372. doi: 10.1038/nrneurol.2014.100
22. Platten M, Ochs K, Lemke D, Opitz C, Wick W. Microenvironmental clues for glioma immunotherapy. **Curr Neurol Neurosci Rep** 2014. 14:440. doi: 10.1007/s11910-014-0440-1
21. Platten M, Wick W. CMV infection and glioma, a highly controversial concept struggling in the clinical arena. **Neuro-Oncol** 2014. 16:332-3. doi: 10.1093/neuonc/nou002
20. Wick W, Wick A, Platten M. Challenging cytomegalovirus data in glioblastoma. **Neuro-Oncol** 2014. 16:165. doi: 10.1093/neuonc/not212
19. Wick W, Wick A, Platten M. Good maths is needed to understand CMV data in glioblastoma. **Int J Cancer** 2014. 134(12):2991-2. doi: 10.1002/ijc.28614

2013

18. Platten M, Lanz T, Diem R. Klinisch isolierte Syndrome. **Nervenarzt** 2013. 84:1247-1259. doi: 10.1007/s00115-013-3845-1
17. Platten M, Wick W, Opitz CA. Immunmodulation durch Tryptophanstoffwechsel: Klinische Relevanz für Autoimmun- und Tumorerkrankungen. **Deut Med Wochenschr** 2013. 138:1478-1482. doi: 10.1055/s-0033-1343222
16. Platten M, Steinbach J, Wick W. Personalisierte Neuroonkologie. **Nervenarzt** 2013. 84:937-942. doi: 10.1007/s00115-013-3758-z

2012

15. Platten M, Wick W, Van den Eynde B. Tryptophan catabolism in cancer – Beyond IDO and tryptophan depletion. **Cancer Res** 2012. 72:5435-40. doi: 10.1158/0008-5472.CAN-12-0569
14. Platten M, Weller M, Wick W. Shaping the glioma immune microenvironment through tryptophan catabolism. **CNS Oncology** 2012. 1:99-106. doi: 10.2217/cns.12.6
13. Platten M, Litzénburger U, Wick W. The aryl hydrocarbon receptor in tumor immunity. **Oncoimmunol** 2012. 1:396-7. doi: 10.4161/inci.19071
12. Platten M, Opitz CA, Wick W. The aryl hydrocarbon receptor as a promoter of malignant glioma. **Cell Cycle** 2012. 11:643-4. doi: 10.4161/cc.11.4.19357

2011

11. Weller M, Platten M, Roth W, Wick W. Geriatric Neurooncology: From Mythology to Biology. **Curr Opin Neurol** 2011. 24:599-604. doi: 10.1097/WCO.0b013e32834c4967
10. Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Pathway inhibition: emerging molecular targets for treating glioblastoma. **Neuro-Oncol** 2011. 13:566-579. doi: 10.1093/neuonc/nor039
9. Wick W, Winkler F, Platten M. Chemotherapy of gliomas. **Onkologe** 2011. 17:44-54. doi: 10.1007/s00761-010-1962-z

2010

8. Bendszus M, Platten M. Neuroradiologische Response-Kriterien für maligne Gliome. **Nervenarzt** 2010. 81:950-5. doi: 10.1007/s00115-010-2959-y

2009

7. Wick W, Seidel C, Wick A, Platten M. Neurooncology in elderly patients. **Nervenheilkunde** 2009. 28:304.

2008

6. Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. **Neuro-Oncol** 2008. 11:69-79. doi: 10.1215/15228517-2008-078

2007

5. Opitz CA, Wick W, Steinman L, Platten M. Tryptophan degradation in autoimmune diseases. **Cell Mol Life Sci** 2007. 64:2542-2563. doi: 10.1007/s00018-007-7140-9

2006

4. Platten M, Ho PP, Steinman L. Anti-inflammatory strategies for the treatment of multiple sclerosis – tryptophan catabolites may hold the key. **Drug Discov Today: Ther Strat** 2006. 3:401-408.

2005

3. Platten M, Steinman L. Multiple Sclerosis: Trapped in deadly glue. **Nat Med** 2005. 11:252-253. doi: 10.1038/nm0305-252

2001

2. Platten M, Wick W, Weller M. Malignant glioma biology: Role for TGF- β in growth, motility, angiogenesis, and immune escape. **Microsc Res Tec** 2001. 52:401-410. doi: 10.1002/1097-0029(20010215)52:4<401::AID-JEMT1025>3.0.CO;2-C
1. Weller M, Wick W, Platten M. Role of TGF- β in oncogenesis. **Microsc Res Tech** 2001. 52:353. doi: 10.1002/1097-0029(20010215)52:4<353::AID-JEMT1019>3.0.CO;2-U